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The treatment of inflammatory bowel disease (IBD) has
been revolutionised over the past decade by the increasing
use of immunomodulators. With such immunomodulation,
the potential for opportunistic infection is a key safety
concern for patients with IBD. Opportunistic infections pose
particular problems for the clinician: they are often
difficult to recognise and are associated with appreciable
morbidity or mortality, because they are potentially serious
and hard to treat effectively. This led the European Crohn's
and Colitis Organisation (ECCO) to update the previous
Consensus meeting on opportunistic infections in IBD. To
organise the work, infections were classified into six major
topics. Guideline statements of 2009 were analysed
systematically by the chairs and the working parties. In
parallel, the working parties performed a systematic
literature search of their topic with the appropriate key
words using Medline/Pubmed and the Cochrane database,
as well as their own files. The evidence level (EL) was
graded according to the 2011 Oxford Centre for
Evidence-Based Medicine (http://www.cebm.net/index.
aspx?o=5653). Provisional update guideline statements
were then posted on a weblog. Discussions and exchange of
the literature evidence among the working party members was
then performed on theweblog. Theworking parties thenmet in
Lille on the 15th–16th of November 2012 to agree on the
statements. Consensus was defined as agreement by
N80% of participants, termed a Consensus Statement and
numbered for convenience in the document.
This paper is the product of work by gastroenterologists,
infectious disease experts and pediatricians. It provides guidance
on the prevention, detection and management of opportunistic
infections in patients of all age categories with IBD. After a
section on definitions and risk factors for developing opportunis-
tic infection, there are five sections on different infectious
agents, followed by a section on information and guidance forpatients with IBD travelling frequently or to less economically
developed countries. In the final section, a systematic work up
and vaccination programme is proposed for consideration in
patients exposed to immunomodulator therapies.
The final document on each topic was written by the
workgroup leader and their working party. Statements are
intended to be read in context with qualifying comments and
not read in isolation. The final text was edited for consistency
of style by JF Rahier, F Magro, R Eliakim and JF Colombel
before being circulated and approved by the participants. In
some areas the level of evidence is generally low, which
reflects the paucity of randomised controlled trials. Conse-
quently expert opinion is included where appropriate.2. Definitions and risk factors
2.1. Definition of an immunocompromised patient
An immunocompromised host has an alteration in phagocytic,
cellular, or humoral immunity that increases the risk of an
infectious complication or an opportunistic process. Patients
may also be immunocompromised if they have a breach of
their skin or mucosal defense barriers that permits microor-
ganisms to cause either local or systemic infection.1 There is
no clearcut definition of an immunocompromised state. Three
categories are recognised by the Centers for Disease Control,2
depending on the severity of immunosuppression:1. Persons who are severely immunocompromised not as
a result of HIV infection: Severe immunosuppression
can be the result of congenital immunodeficiency,
leukemia, lymphoma, generalised malignancy or thera-
py with alkylating agents, antimetabolites, radiation, or
high doses of corticosteroids (2 mg/kg body weight, or
N20 mg/day of prednisolone, Section 2.4.1)
2. Persons with HIV infection
3. Persons with conditions that cause limited immune
deficits (e.g. hyposplenism and renal failure)
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An opportunistic infection may be defined as a usually
progressive infection by a microorganism that has limited (or
no) pathogenic capacity under ordinary circumstances, but
which is able to cause serious disease as a result
of the predisposing effect of another disease or of its treatment.3
2.3.Whatmakes an IBD patient immunocompromised?ECCO Statement OI 2A
Patients with IBD should not be routinely considered to
have altered immunocompetence [EL5] per se, despite
evidence of impaired innate mucosal immunity. Differ-
ent immunomodulators may alter immune responsive-
ness by different mechanisms and to varying degrees,
but there is currently no single method of evaluating
the effects of immunosuppression on the immune
system [EL5] ECCO Statement OI 2B
IBD patients at risk of opportunistic infections are those
treated with immunomodulators [EL1], especially in
combination [EL3], and those with malnutrition [EL5].
In addition, co-morbidities and a history of serious
infections should be considered. Age is an independent
risk factor for opportunistic infections in IBD [EL3]From genome wide association studies there is increas-
ing evidence of an aberrant immune response in IBD.4
Susceptibility loci involve both the innate and adaptive
immune response towards a diminished diversity of com-
mensal microbiota.5 Description of the numerous mecha-
nisms contributing to this dysimmunity is beyond the scope
of this article. Despite evidence of defective mucosal
immunity, there is no proof of a systemic immune defect
in patients with IBD in the absence of concomitant
immunomodulator therapy.
Patients with IBD are therefore rendered immunocom-
promised through their treatment. Immunomodulators
commonly used in inflammatory bowel disease are corti-
costeroids, thiopurines, methotrexate, calcineurin inhibi-
tors, anti-tumor necrosis factor agents, or other biologics.
Their modes of action differ, but they all compromise to
some extent the patient's immune response. To date there
is no accurate biological means to quantify immunosup-
pression in patients with IBD.
2.4. Risk factors for developing an opportunistic
infectionECCO Statement OI 2C
The immunomodulators commonly used in IBD and
associated with an increased risk of infections include
corticosteroids, thiopurines, methotrexate, calcine-
urin inhibitors, anti-TNF agents and other biologics
[EL1]. For corticosteroids, a total daily dose equivalent
to ≥20 mg of prednisolone for ≥2 weeks is associated
with an increased risk of infections [EL3]Predisposing factors not only lower the patient's
resistance to opportunistic infection, but enable the
infection to develop and progress to an extent that is
not otherwise seen.3 Only few data are available
regarding risks factors for developing an opportunistic
infection. In a recent study infection-related
hospitalisations were independently associated with age,
co-morbidity, malnutrition, total parenteral nutrition, and
bowel surgery.6 Information was therefore also collected from
patients with rheumatological disease and from the general
population. We have defined two categories of risk: those that
are external to the patient (immunomodulator therapy,
exposure to pathogens, or geographic clustering) and those
that are inherent to the patient (age, comorbidity and
malnutrition).2.4.1. Immunomodulator therapyViral, bacterial, parasitic and fungal infections have all been
associated with the use of immunomodulator therapy in IBD.
Despite different mechanisms of action, any of those drugs can
lead to any type of infection. No strict correlation between a
specific immunomodulator drug and a certain type of infection
has been observed. Toruner and colleagues found that
corticosteroid use was more commonly associated with fungal
(Candida spp.) infections, azathioprine with viral infections and
anti-TNF therapy with fungal or mycobacterial infections.7
There was, however, considerable overlap. Furthermore, these
drugs are commonly prescribed together, so the infectious
event might be the consequence of cumulative immunosup-
pressive activity.
Data that identify immunomodulators as risk factors for
opportunistic infection come mainly from the rheumatologic
literature.8 Corticosteroids are dose dependently linked to
increased risk of both serious9,10 and non-serious infections
(NSI) in rheumatoid arthritis (RA).11 Relative risks for NSIs in
one study were 1.10 and 1.85 with prednisolone dosed at
b5 mg/d and N20 mg/d respectively.11 In the CORRONA
registry the RR for all infectious events was increased with
N10 mg/d (RR 1.30) whilst any dose increased the risk of
opportunistic infection (RR 1.67).12 There are no precise data
in the IBD population that identify a dose associated with
increased risk of infection. The risk of post-operative infec-
tions has been linked to concurrent use of corticosteroids in IBD
patients undergoing elective surgery.13 Both corticosteroids
and anti-TNF therapy independently, and more significantly
446 J.F. Rahier et al.in combination, increased the risks of post-operative
intra-abdominal infectious complications in a retrospec-
tive study of 3 referral centres.14 In this setting, a recent
meta-analysis has shown anti-TNF therapy to increase
post-operative infectious complications in Crohn's
disease (OR 1.45) but not ulcerative colitis.15 However,
a different group of authors did not demonstrate
an increased risk with anti-TNF therapy for all post-
operative complications.16
Anti-TNF therapy is associated with increased rates of
serious bacterial infection in RA, especially in the first
6 months of treatment initiation.17 Rates of opportunis-
tic infections, serious infections and of septic arthritis
were increased in anti-TNF treated RA patients as
reported in the CORRONA, RABBIT and British Society
for Rheumatology biologics registries respective-
ly.10,12,18 The TREAT registry showed an increased risk
of serious infections with anti-TNF therapy in Crohn's
disease (hazard ratio 1.47), albeit less than that for
corticosteroids (HR 1.57) and narcotics (HR 1.98).19 A
recent meta-analysis of all published data from 22
randomised controlled trials in IBD, demonstrated a 2
fold increased risk of opportunistic infections with
anti-TNF therapy.20
Each immunomodulator carries an increased risk of
infection, although to a varying degree that has not yet
been quantified. Of fundamental importance is the
observation that combinations of immunomodulator ther-
apy in IBD are associated with an incremental increase in
the relative risk of opportunistic infection (three fold
increased risk (OR 2.9, 95% CI 1.5–5.3) if any one
immunomodulator was used, increasing substantially (OR
14.5, 95% CI 4.9–43) if two or more drugs were used
concomitantly).72.4.2. Exposure to pathogens and geographic clusteringECCO Statement OI 2D
Exposure to microbial microorganisms is a risk factor
for opportunistic infection in the immunocompromised
population. Avoiding contact with potential sources
including recent recipients of certain live vaccines and
travel to endemic areas may reduce the risk of
infection in IBD patients on immunomodulators [EL5]Special consideration should be given to patients from
endemic areas, and patients who appear not to be
responding to immunomodulators as expected. For path-
ogens that are ubiquitous, it is impractical to reduce
exposure. However, it is logical to avoid high intensity
exposure (such as sharing a room with a person, including
a child, with active infection or recent recipients of
certain live virus vaccines). Living in an area where
tuberculosis or other diseases such as histoplasmosis orcoccidioidomycosis are endemic, inevitably increases the
risk for contracting an opportunistic infection in the
normal population, let alone those who are on immuno-
modulator therapy.21
Several microorganisms have been shown to be capable
of replicating in water. In addition, both municipal water
and ice cubes in drinks have been the source of
nosocomial outbreaks of infection. In less economically
developed countries, the immunocompromised patient
may best be advised to avoid tap water and ice made
from tap water.222.4.3. Age
Immunosenescence is defined as the state of dysregulat-
ed immune function that contributes to an increased
susceptibility of the elderly to infection and possibly to
autoimmune disease and cancer.23 In this population,
there is good evidence of functional alterations in cells
from the innate and adaptive immune systems.24–26
Nevertheless, there is surprisingly little evidence that
immune dysregulation has direct relevance to the
infections commonly seen in the elderly population,
except e.g. reactivation of tuberculosis. On the other
hand, there are data to demonstrate that infections with
pyogenic bacteria, such as community-acquired pneumo-
nia and urinary tract infections are 3 to 20 fold more
prevalent in the elderly than in younger adults. In
contrast, viral infections are rare in comparison
with the younger population, with the exceptions of
influenza, reactivation of herpes zoster and viral
gastroenteritis.24
In IBD age has been described as an independent risk
factor for infection-related hospitalisations.6 A
case-controlled study of 100 patients identified age N50 as
a predisposing factor for opportunistic infections (OR 3.0,
95% CI 1.2–7.2 relative to age b25 yr).7 This finding was
supported by Naganuma et al., who also showed an
increased incidence of opportunistic infections in patients
aged 50 years or older.25 Along the same line, Cottone et
al. described higher rates of severe infections and
mortality in patients older than 65 years treated with
TNF inhibitors for IBD as compared with younger patients
or peers treated without these compounds.26 Thus, it is of
relevance to remain cautious when treating elderly
patients with immunosuppressive agents, including TNF
inhibitors. Increasing age has also been identified as a
significant predictor of infection in a cohort with rheuma-
toid arthritis.27
The available evidence in the paediatric IBD litera-
ture shows that immunosuppression increases the risk
for infections, but these infections usually seem mild.
However, a retrospective study from 20 countries on
mortality in paediatric IBD (b19 years) revealed 15 cases
who died due to an infection within 5 years.28 In early life
(b1 year of age) severe forms of IBD are distinct clinical
entities and may be combined with specific immune
defects such as interleukin-10 receptor defects, altered
regulatory T cell function and decreased FOXp3 protein
levels.29 These patients are known to develop severe
complications such as EBV-induced lymphoproliferative
disorder.
ECCO Statement OI 3A
Screening for hepatitis C (HCV) using antibody testing
should be considered. If positive, it should be con-
firmed by detection of HCV RNA. This is important due
to the potential risk of worsening liver function as a
result of immunosuppressive therapy, concomitant
infection with other viruses, (HBV/HIV) or by potenti-
ating the effects of hepatotoxic medications [EL3].
Immunomodulators may influence active chronic HCV
(HCVAb+, HCV RNA+) infection. They are not contra-
indicated but should be used with caution [EL3]. The
decision depends on the severity of IBD and the stage of
the liver disease. The risk that anti-viral therapy or
drug interactions with IBD therapy might exacerbate
IBD should be weighed cautiously when considering the
need for HCV treatment [EL3]
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Four comorbidities have been identified as significant risk
factors for infection in rheumatoid arthritis patients: chronic
lung disease, alcoholism, organic brain disease and diabetes
mellitus.30 In IBD comorbidities have been described in
general as an independent risk factor for infection-related
hospitalisations,6 though lacking further specification. Prag-
matic caution is advisable when considering immunomodulator
therapy in patients with comorbid conditions.
2.4.5. Malnutrition
At malnutrition, the immune system is deprived of the
components needed to generate an effective immune
response. The immune response can in turn influence
nutritional status, since TNFα has a profound influence on
nutrient absorption and metabolism.31 Nutritional deficiency
is associated with impaired cell-mediated immunity, as
well as decreased phagocyte function, cytokine produc-
tion, secretory antibody affinity and response, and impair-
ment of the complement system.32 Immune disorders
related to nutritional deficiency range from increased
opportunistic infections and cancers to suboptimal re-
sponses to vaccinations.31 Consistent with cause and
effect, supplements of micronutrients improve immune
responses, reduce the incidence of respiratory infections
and ameliorate the impaired response to vaccination.32
Nutritional deficiency is common in Crohn's disease
and micronutrient deficiency (such as to zinc, copper, or
selenium) often go unrecognised. A person at “nutritional
risk” is someone whose consumption and/or absorption of
specific nutrients is deficient.31 Numerous factors contrib-
ute to malnutrition in IBD: anorexia (due to increased
levels of cytokines); drug–nutrient interaction (corticoste-
roids decrease intestinal absorption and increase renal
excretion of calcium; sulfasalazine decreases folate absorp-
tion); malabsorption (bacterial overgrowth causing steator-
rhoea affects fat-soluble vitamins and B12 absorption);
inadequate intake (fear of abdominal pain, or altered taste
sensation with metronidazole); reduced caloric intake due
to partial small bowel obstruction; ileal resection (vitamin
B12); and jejunal disease or resection (iron deficiency), let
alone short bowel syndrome.33 Depressed cellular immunity
has been observed in malnourished CD, both in vivo and in
vitro.34 Nevertheless, the correlation between malnutrition
and risk of infection has not been extensively studied in IBD.
Malnutrition has been described as an independent risk factor
for infection-related hospitalisations.6 Yamamoto et al. found
an increased risk of intra-abdominal septic complications in
patients with an albumin level b30 g/L.35 It is still unclear
whether this was cause or consequence, since a low serum
albumin often reflects decreased synthesis as a consequence of
infection or disease activity and is not a good way of assessing
malnutrition in IBD patients. By comparison, a low serum total
protein or albumin has been associated with opportunistic
infection in patients with polymyositis or dermatomyositis.36
Better measures of nutritional status are the body mass
index (BMI) and the simple expedient of asking a dietitian
to conduct a formal nutritional assessment of intake and
expenditure. Evaluation is readily achieved when a dietitian
is part of the IBD service, conducting a clinic parallel to
an IBD clinic. Formal dietetic assessment and nutritional
support when starting immunomodulator therapy (or, indeedwhen considering surgery) in those with a BMI b20 kg/m2
could readily be implemented in clinical practice.
3. Hepatitis C virus (HCV), hepatitis B virus
(HBV) and human immunodeficiency virus (HIV)
3.1. Hepatitis C virus infection3.1.1. Background
See supplementary material.
3.1.2. Impact of immunomodulator therapy on the natural
history of the disease
The largest series assessing the outcome of HCV infection in
patients with IBD and its relation to immunomodulator
therapy revealed liver dysfunction in 8/51 HCV RNA positive
patients (16%). No cases of HCV RNA reappearance were
observed in 23 additional anti-HCV positive patients with
negative HCV RNA. Impaired liver function tests were
related to corticosteroids given alone and in one case to
azathioprine. The severity of hepatic dysfunction was
clearly lower for HCV than for HBV although one patient
died of liver failure while receiving corticosteroids. This
patient also had anti-HBc positive markers without anti-HBs
and tested positive for antibodies against HIV, suggesting
the existence of an occult HBV infection. Therefore
co-infection was probably the cause of fatal outcome.37 In
fact, there is a fairly general agreement in considering HCV
infected patients as the category of individuals with the
highest prevalence of occult HBV, mainly in Mediterranean
and Far East Asian countries.38 In vitro studies have clearly
demonstrated that the HCV “core” protein strongly inhibits
HBV replication.39
The influence of corticosteroids on HCV-related liver
disease progression has been demonstrated in liver
ECCO Statement OI 3B
All IBD patients should be tested for HBV (HBsAg, anti-
HBAbs, anti-HBcAb) at diagnosis of IBD to determine
HBV status. In patients with positive HBsAg, viremia
(HBV-DNA) should also be quantified [EL2]
ECCO Statement OI 3C
HBV vaccination is recommended in all HBV anti-HBcAb
seronegative patients with IBD. [EL1]. Efficacy of
hepatitis B vaccination is impaired in IBD, probably by
the disease itself and by anti-TNF drugs. Anti-HBs
response should be measured after vaccination. Higher
doses of the immunizing antigen may be required to
provide protection [EL 2]. Maintenance of HBs antibody
should be monitored in patients at risk [EL 5]
ECCO Statement OI 3D
Before, during and for at least 12 months after immuno-
modulator treatment has ceased, patients who are HBsAg
positive (chronic HBV infection) should receive potent
anti-viral agents (nucleoside/nucleotide analogues with
high barrier to resistance) regardless of the degree of
viremia in order to avoid hepatitis B flare [EL2]
ECCO Statement OI 3E
Patients with positive HBcAb and negative HBsAg may
have occult HBV infection. Reactivation of occult HBV
rarely occurs with immunosuppressive therapy used in
IBD [EL2]. Viremia (HBV DNA) should be assessed every
2–3 months but antiviral therapy is not recommended
unless HBV-DNA is detected [EL5]
3.2. Hepatitis B virus (HBV) infection
448 J.F. Rahier et al.transplant patients in whom steroid boluses are associated
with increased viremia, fibrosis progression, and reduced
survival. Currently, the only specific recommendation in
this setting is the avoidance of overimmunosuppression
(particularly corticosteroid boluses). By contrast, progres-
sion to liver cirrhosis in immunosuppressed IBD patients seems
to be similar to that observed in non-immunosuppressed
infected patients.40 Thus, administration of immunosuppres-
sants, as is common in IBD, does not seem to have a significant
detrimental effect on the course of HCV and does not increase
progression to end-stage liver disease except for cases of
co-infection with HBV and/or HIV in whom severe liver failure
may occur.
In addition, a recent systematic review including 37
publications with data on 153 HCV infected patients who
were treated with anti-TNF agents, mainly for rheumatoid
arthritis, only found one definitely confirmed case of HCV
worsening.41 Moreover, the best evidence that anti-TNF
therapy might even be beneficial for HCV infection comes
from a study of etanercept as an adjuvant to interferon
and ribavirin therapy for naïve patients with chronic
HCVinfection.42 Anti-TNF strategy seems to improve viro-
logical response to a combined IFN-α2b/ribavirin therapy
in these patients. A small series of hepatitis C patients
with arthropathy treated with methotrexate showed no
detrimental effect from treatment with methotrexate.43
3.1.3. Preventive measures
General measures to reduce or prevent HCV infection
are appropriate, since vaccination or chemoprophylaxis for
potential infection is not available.
3.1.4. Diagnostic approach, screening and treatment of
underlying infection
3.1.4.1. Diagnostic approach and screening. In previous
European evidence-based Consensus44 no agreement could
be reached for HCV screening (including HCV antibody
testing or HCV PCR in the event of positive antibody testing)
prior to starting immunomodulators. Based on present knowl-
edge, showing in some cases a mild liver dysfunction and
amplified detrimental effect with other viruses (HBV/HIV)
related to immunomodulators, HCV antibody testing and HCV
PCR should be determined.
3.1.5. Treatment of the infection
Immunodulators can be used in IBD patients regardless of
concomitant HCV infection. On the other hand, antiviral
treatment for HCV infection in conjunction with Crohn's
disease is generally not recommended, since interferon
therapy may worsen disease, although this remains controver-
sial.45 This is in contrast to ulcerative colitis where interferon
therapy does not appear to have an adverse effect.46
Telaprevir and boceprevir, the HCV protease inhibitors, are
inhibitors of the enzyme cytochrome P450 3A, which is
responsible for the metabolism of both cyclosporine and
tacrolimus. It has recently been demonstrated in healthy
volunteers that telaprevir increased the blood concentrations
of both cyclosporine and tacrolimus significantly, which could
lead to serious or life threatening adverse events.47 In addition
the administration of ribavirin plus interferon or the recently
introduced triple antiviral therapy (interferon, rivabirin andprotease inhibitors) may increase toxicity of drugs used for IBD
maintenance (for example azathioprine,methotrexate). Thus,
the risk of IBD worsening by anti-viral therapy or drug
interactions with IBD therapy should be cautiously weighted
when considering the need of HCV treatment and warrants
careful consideration on an individual case basis.3.1.6. Infection occurring during immunomodulator therapy
There are no reports of acute HCV infection developing
during immunomodulator therapy. Interruption of immuno-
modulator therapy is not necessarily recommended.
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See supplementary material.
3.2.2. Impact of immunomodulator therapy on the natural
history of HBV infection in IBD
Reactivation of HBV is a well-described complication of
immunosuppression in the setting of organ transplantation or
cancer chemotherapy occurring in up to 50% if anti-viral
therapy is not administered. Administration of pre-emptive
therapy in immunosuppressed patients infected with HBV is
well-established by scientific societies.55 Consequently, the
influence of immunomodulators on the course of untreated
HBV infection in IBD will never be studied prospectively. The
first reported cases of reactivation of HBV in IBD were
described after infliximab treatment and have been exten-
sively reviewed elsewhere.56,57
However, the majority of these cases were receiving
concomitantly other immunomodulators such as corticoste-
roids or thiopurines, suggesting that more profound immu-
nosuppression may facilitate viral reactivation. Two large
retrospective cohort studies assessing the outcome of HBV
infection in IBD patients and its relation to immunosuppres-
sive therapy (corticosteroids, immunomodulators, and/or
anti-TNFα therapy) have recently been published.37,58 Liver
dysfunction occurred in 25 to 36% of HBsAg-positive IBD
patients treated with immunosuppressants. In one of these
studies, more than 50% of patients with HBV reactivation had
liver failure with one patient dying. The information
provided is clinically relevant since the type, duration and
combination of immunomodulators differs in IBD from that
used in oncological therapy and in other inflammatory
conditions requiring immunomodulators. In this regard,
most of the HBV-infected patients who had reactivation
were receiving treatment with 2 or more immunomodulators
for a long period of time, were positive for HBV-DNA and/or
had not received prophylactic antiviral treatment.
HBV reactivation was described in a Crohn's disease patient
with anti-HBcAb+ and HBsAg− treated with corticosteroids
and infliximab.59 However, reactivation of occult HBV
infection seems to be extremely rare with the immunosup-
pression used in IBD,37,60 in contrast to patients undergoing
oncological chemotherapy, particularly rituximab.61
3.2.3. Diagnostic approach, screening, prevention and
treatment
All IBD patients have to be tested for HBV infection (HBsAg,
anti-Hbs, anti-HBc) to assess infection or vaccination status. In
patients presenting with evidence of HBV infection, HBeAg,
anti HBe, and HBV DNA should also be assessed.
3.2.3.1. Vaccination in seronegative patients. The bur-
den caused by HBV infection, particularly in IBD, justifies
systematic vaccination of all seronegative patients (anti-
Hbs− , anti-HBc− ). In low endemicity countries the need
for universal vaccination has been questioned.62,63 Howev-
er, the World Health Organization (WHO) recently recom-
mended the administration of HBV vaccine as soon as possible
after birth not only in countries with high endemicity but also
in intermediate or low endemicity areas.64
The prevalence of HBV infection in IBD is similar than that
observed in the reference population.60,65,66 However, the
influx of immigrants from endemic to low prevalence areasmay affect HBV prevalence at a local level. In this sense, the
expected increased integration of immigrant and indigenous
populations may cause transmission of HBV to non-immunised
individuals. Moreover, travelers from low to high-risk areas,
frequently young people with a low perception of risk, often
undertake many high-risk behaviors.
The standard vaccination (rHBAg 20 μg single dose at 0, 1
and 6 months) is ineffective to obtain seroprotection in the
majority of non-previously vaccinated IBD patients, partic-
ularly in those treated with immunosuppressants.67–69
The administrations of accelerated double-dose at
0,1,2 months followed by re-vaccination (0, 1, and
2 months) at a double dose if no adequate response is
achieved has demonstrated a better efficacy than the
standard schedule (60 to 70% efficacy).70
The serological response should be assessed 1 to 2 months
after the last dose. Sincemany patients will lose seroprotection
after successful vaccination (18% per patient-year), levels
of anti-HBs N 100 IU/l are advisable to achieve adequate
seroprotection particularly if anti-TNF treatment is planned.71
On the other hand, a unique booster dose has demonstrated to
restore immune response in pediatric patients who had lost
seroprotection and is the recommended schedule in these
cases.72 The frequency of monitoring is not well established
but check-ups for anti-HBs yearly or every 2 years seems
reasonable mainly in countries with intermediate and high
endemicity.
3.2.3.2. Prevention and/or treatment of reactivation in
seropositive patients with chronic HBV infection (HBsAg+). In
HBsAg+ patients, prophylactic antiviral treatment with nucle-
otide/nucleoside analogues is recommended, best started
2 weeks prior to the introduction of immunomodulators and
continued for 12 months after their withdrawal. Patients with
high baseline HBV DNA levels (N2000 IU/mL), should continue
antiviral treatment until endpoints applicable to immunocom-
petent patients are reached, according to specific guidelines
for HBV treatment.73,74 A number of case series and study
cohorts suggest that nucleotide/nucleoside analogues are safe
and effective in IBD patients on immunomodulator treat-
ment.75 Entecavir and tenefovir are the preferred anti-virals
for IBD patients due to their rapid onset of action, highest
anti-viral potency and low incidence of resistance. In IBD, a
rapid control of HBV infection is required particularly when the
administration of immunosuppressants may not be delayed. In
addition, the need of long-term immunosuppression requires
anti-viral treatments with a high genetic barrier and very low
incidence of resistance. Peginterferon-alpha-2a (IFNα) is best
avoided for two reasons: first, IFNα may exacerbate Crohn's
disease but not ulcerative colitis46 and second, IFNαmay cause
additional bone marrow suppression.
3.2.3.3. Prevention of reactivation in seropositive patients
with evidence of past HBV infection (HBsAg−, anti-HBcAb+
with or without anti-HBsAb). As previously mentioned, HBV
reactivation may occur in patients who are HBsAg-negative
but anti-HBc and anti-HBs-positive, as well as in those with
isolated anti-HBc.59 Retrospective and prospective stud-
ies37,60 suggest however that reactivation of occult HBV
in IBD rarely occurs. Thus, routine prophylaxis for these
individuals is not recommended. These patients should be
monitored routinely for elevation of AST/ALT, as well as for
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while on immunomodulator therapy based on EASL Clinical
Practice Guidelines 2012.73
3.2.4. Acute Infection occurring during immunomodulator
therapy
There are no reports of newly acquired (acute) HBV infection
during immunomodulator or biological therapies. Apart from
fulminant hepatitis, where expert opinion has advocated
nucleotide/nucleoside treatment, there is no established
treatment for acute HBV infection. HBV infection in immuno-
competent adults resolves in the vast majority of patients.
However immunomodulators might worsen disease or increase
the chance of chronic infection. This has been demonstrated for
corticosteroids which increase the replication rate of HBV by
direct effects on viral replication as well as inhibition of the
immune response. In IBD patients with acute HBV infection,
immunomodulators and/or biologics should be delayed or
stopped until resolution of the acute infection or reactivation
(HBV DNA levels b 2000 IU/mL). In these cases nucleotide/
nucleoside treatment is recommended in acute infection as it is
for HBV reactivation.
3.3. Human immunodeficiency virus (HIV) infectionECCO Statement OI 3F
Testing for HIV is recommended for adolescent and
adult patients with IBD, and should always precede
commencement of immunomodulator therapy, based
on reports of increased risk and severity of HIV-related
infections in patients receiving immunomodulator
therapy [EL4]. However, immunomodulators are not
necessarily contraindicated in HIV-infected patients
[EL4]. Re-testing is indicated for patients at risk [EL 5]3.3.1. Background
See supplementary material.
3.3.2. Impact of immunomodulator therapy on the natural
history of the disease
The effect of corticosteroids on the course of HIV infection in
IBD patients has been scarcely studied. Corticosteroids are
used as adjunctive therapy in the treatment of complications
of HIV infections such as lymphoma or Pneumocystis jiroveci
infection.76 A recent observational study demonstrated that
patients receiving low-dose prednisolone (5 mg/day) showed
significantly lower general cellular immune activation than
untreated patients. However, it is unknown if this dose which
is clearly lower than that used to treat IBD relapses, has a
beneficial effect in HIV disease progression.77 It is reasonable
to use corticosteroids for the therapy of IBD patients with
HIV infection receiving HAART who have achieved immune
reconstitution and undetectable viral loads, but no data are
available. Information regarding the use of azathioprine and
its effect on HIV infection in IBD patients is very limited. A
case–control study, with a long term follow-up, compared20 HIV infected IBD patients with 40 non-HIV infected IBD
showing lower relapse rates in HIV infected patients
than in non-infected ones. Six HIV infected patients
were receiving azathioprine without any reported adverse
outcome. The majority of these patients were receiving
HAART therapy.78
TNF-α has been implicated in the pathogenesis of HIV
infection, by contributing to HIV replication through activation
of NF-кB.79 Increased TNF-α concentrations have also been
associated with advanced stages of HIV infection and the
occurrence of infectious complications. It has also been
proposed that increased circulating TNF-α, interpreted as a
reflection of a frustrated immune response unable to control
HIV,80 may even accelerate the disease.81 There are, however
some studies on the effects of anti-TNF-α therapy on the
course of HIV infection which have been reviewed.82 Case
reports and small series of IBD patients or patients with
rheumatic diseases have indicated that neither infliximab
nor etanercept worsened in general HIV infection.78,83–86 A
unique report described a reduction in HIV virus load after
infliximab infusion in a non HAART-treated HIV-patient.87 A
study investigated the effect of a four week therapy with
etanercept (25 mg twice weekly) in 16 untreated HIV patients
with smear positive tuberculosis and CD4+ cells N200/mm3.
The clinical response to antituberculous chemotherapy was
at equivalent or superior to a historical treatment group,88
although it is difficult to recommend such a high-risk strategy.
These data suggest that anti-TNF therapy may be given to IBD
patients with coexisting HIV infection and might not have the
detrimental effects on HIV infection.78,83,84 Therefore, HIV
patients may be treatedwith immunosuppressants if necessary
by the clinical pattern of IBD but they should be carefully and
closely monitored.
3.3.3. Preventive measures
General measures to prevent HIV infection are appropriate.
These include educational initiatives to avoid sexual
transmission by using condoms and avoiding shared needles
in intravenous drug users. Post-exposure prophylaxis is
appropriate for health professionals exposed to contami-
nated injection needles or blood from HIV-positive individ-
uals. Local guidelines are likely to be available and
specialist advice is appropriate.
3.3.4. Diagnostic approach, screening and treatment of
the underlying infection
3.3.4.1. Diagnostic approach and screening. All IBD
patients undergoing immunomodulator or biological therapy
are best tested for HIV infection (through HIV p24 antigen and
antibody testing, with PCR only if acute infection is suspected)
to rule out unknown infection, because of the potential
consequence of such therapy in HIV patients. It is reasonable
to take the risk of acquiring HIV into account. The diagnosis of
inflammatory bowel disease in HIV-infected patients should be
reviewed and treatment managed in conjunction with
appropriate specialists.
3.3.4.2. Treatment of the infection. Due to the scarce
clinical data on the effect of immune reconstitution following
treatment with HAART on the course of concomitant HIV and
IBD, no recommendations are available.82 It is reasonable to
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immune reconstitution, so that HIV-infected IBD patients will
have fewer infectious complications from immunosuppressive
IBD therapy than if they did not receive HAART. The
susceptibility to infection of IBD patients suffering from HIV
greatly depends on the success of HAART. When the CD4+
count is N350/μl the risk may be little different to those
without HIV, but CD4 count less than 200 increases the risk.
Aboulafia et al. reports the death of a HIV-infected man
treated with etanercept for psoriasis of bacterial infection.
He was receiving HAART but his CD4 count was 56/μl.89
However, potential interactions between immunomodulators
and HAART, apart from possible modification of the success of
HAART, are largely unknown. There may be cumulative,
additive, synergistic, or antagonistic effects of the different
drugs in terms of pharmacokinetics, pharmacodynamics, or
side effects (www.hiv-druginteractions.org).
3.3.5. Infection occurring during immunomodulator therapy
Primary HIV infection can occur during immunomodula-
tor therapy but its occurrence should be rare. One case-
report described a woman with Crohn's disease who
acquired primary HIV infection during therapy with azathi-
oprine, with HAART prescribed at this moment for one
year.87 From a practical point of view, symptomatic HIV
infection should be treated according to discussion with
appropriate specialists. Interruption of immunomodulator
or biological therapy should be considered if there is no
response to HAART (either by clinical improvement, or
increase in CD4+ count).
4. Herpesviruses (HSV, VZV, EBV, CMV), human
papilloma virus, and influenza virus
4.1. Cytomegalovirus (CMV) infectionECCO statement OI 4A
Screening for CMV infection is not necessary before
starting immunomodulator therapy [EL4]. In patients with
acute steroid-resistant colitis, CMV should be excluded,
preferably by tissue PCR or immunohistochemistry, before
increasing immunomodulator therapy [EL3]. In case of
severe steroid-resistant colitis with CMV detected in the
mucosa during immunomodulator therapy, antiviral ther-
apy should be initiated and discontinuation of immuno-
modulators considered until colitis symptoms improve
[EL5]. In case of systemic CMV disease, immunomodulator4.1.1. Background
See supplementary material.
4.1.2. Impact of immunomodulator therapy on natural
history of the disease
Immunomodulator therapy is often associated with subclinical
reactivation of latent CMV infection.106 This reactivation is
usually asymptomatic, or characterised by a mild, self-limited
therapy must be discontinued [EL2]course. Serious tissue damage is very rare.90,107 It is appropriate
to draw a distinction between CMV infection (detectable by
serology or viral DNA), and CMV disease (such as colitis, causing
end-organ damage). Matsuoka et al. have demonstrated
that CMV is frequently reactivated in patients with UC
treated with steroids or 6-mercatopurine, but disappears
without antiviral therapy.108 In their series, CMVantigen
concentrations were low in all patients and none had clinical
symptoms or CMV detected in biopsy specimens. These data
agree with previous studies showing that subclinical reactiva-
tion of CMV during immunomodulator or biological therapy is
common, but nearly always self-limited even if therapy is
continued.109–113 Consequently, with the exception of severe
infection (see below), immunomodulator treatment may be
continued during CMV reactivation.
4.1.3. Preventive measures
There is no CMV vaccine available. Although different
nucleoside analogues are effective therapy for severe CMV
infection, the potential for adverse events does not justify
standard chemoprophylaxis.90,91,106
4.1.4. Diagnostic approach, screening and treatment of
the underlying infection
4.1.4.1. Diagnostic approach and screening. Only a minor-
ity of CMV infections lead to clinical disease, so screening for
subclinical CMV infection in IBD patients is not indicated
unless the patients are steroid resistant.
Different techniques for the diagnosis of CMV infection are
available. The high seroprevalence in the adult population
means that serology is of limited value for the diagnosis of
active infection, but detection of CMV-specific antibodies can
be used to diagnose recent infection (CMV IgM, change in IgG
concentration, or IgG avidity). This identifies patients at risk
from CMV reactivation (CMV IgG positive).91 Conventional viral
culture and the faster shell vial culture are highly specific, but
have disadvantages including long incubation, lack of viral
quantification, false-negative results if cell culture inoculation
is delayed, and lower sensitivity compared to antigenaemia
assays or PCR. CMV antigenaemia assays are only semiquanti-
tative, but act as an indirect marker of disseminated infection.
They are sufficiently rapid to monitor infection and antiviral
treatment in immunocompromised patients, if measurement of
viral load by PCR is not readily available.91,113 Histopathology
combined with immunohistochemistry (IHC, using monoclonal
antibodies against CMV immediate early antigen) are highly
specific and sensitive for verifying CMV infection in tissue or
biopsies. The most commonly used technique for diagnosis of
CMV infection and disease is detection of CMV DNA through PCR
in tissue biopsies and in the blood. The advantages of PCR are
rapid results, high sensitivity, the potential for qualitative and
quantitative testing, detection in a wide range of samples
(whole blood, buffy coat specimens, bronchoalveolar lavage
(BAL) fluid and stool) and applicability in neutropenic pa-
tients.91,94,113 In patients with severe colitis, CMV has been
reported in colonic tissue in 21–34% and in 33–36% of
steroidrefractory colitis.104 The viral load (N250copies/mg)
has been shown to be a predictor of steroid resistant disease.114
4.1.4.2. Treatment of the infection. Ganciclovir (for
2–3 weeks) is the therapy of choice for CMV infections.
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of the 2- to 3-week course may be considered if available,
depending on the clinical course and local specialist
advice.97,98,114 In cases of ganciclovir resistance or intol-
erance (e.g. myelotoxicity), foscarnet (for 2–3 weeks) is
an alternative.105,106
4.1.5. Infection occurring during immunomodulator therapy
Subclinical or mildly symptomatic reactivation does not require
treatment or interruption of immunomodulator therapy and
usually passes unrecognised.107 Systemic CMV reactivation
causing meningo-encephalitis, pneumonitis, hepatitis,
oesophagitis, or colitis, is rare, but associated with a poor
outcome.94,96,98 Prompt antiviral treatment with ganciclovir or
other agents and discontinuation of immunosuppressive agents
is associated with clinical improvement and decreased
mortality,94–98 so are recommended.
4.2. Herpes simplex virus (HSV)ECCO Statement OI 4B
Screening for HSV infection is not necessary prior
to initiation of immunomodulator therapy [EL2]. HSV
infection is not a contraindication to immunomodulator
therapy [EL2]. The need for oral suppressive antiviral
therapy should be considered in patients with recurrent
oral or genital HSV infection at commencement, or arising
during immunomodulator therapy [EL2]. If there is a
clinical suspicion, HSV colitis is best excluded by immuno-
histochemistry or tissue PCR as a cause of immunomodu-
latory refractory IBD before increasing immunomodulator
therapy [EL4]. In the event of severe HSV disease during
immunomodulator therapy, antiviral therapy should be
initiated and immunomodulators discontinued until symp-
toms improve [EL4]ECCO Statement OI 4C
At diagnosis of IBD, patients should be screened by history
for susceptibility to primary VZV infection. Those without
a clear history of chickenpox, shingles or receipt of two
doses of varicella vaccine should be tested for VZV IgG
[EL2]. Where possible, seronegative patients should
complete the two dose course of varicella vaccine at least
3 weeks prior to commencement of immunomodulator
therapy [EL5]. Subsequent immunisation can only be
administered after a 3–6 month cessation of all immuno-
suppressive therapy [EL4]. Seronegative patients should
receive timely post-exposure prophylaxis [EL4]4.2.1. Background
See supplementary material.
4.2.2. Impact of immunomodulator therapy on natural
history of the disease
Primary or recurrent oral and genital herpes may be more
frequent, severe and extensive in immunocompromised
patients.115,116 In a prospective study, IBD patients receiv-
ing azathioprine therapy self-reported significantly more
skin or genital herpetic flares compared with patients on
mesalazine.118Reactivation may cause severe localised
systemic infections with significant morbidity and mortality
including encephalitis,119–121 meningitis,122 pneumonia,123
oesophagitis,124 and colitis.125–129 HSV has increased potential
for dissemination in immunocompromised individuals.130,131
Fulminant herpes simplex hepatitis may be the initial
manifestation of disseminated HSV disease.132,133 This rare
but devastating complication of HSV is more common even in
marginally immunocompromised individuals.134
4.2.3. Preventive measures
There is no vaccine available for HSV.135,136 Patients should be
asked if they have a history of orolabial, genital or ophthalmicHSV infection, prior to immunosuppressive therapy.137 Spe-
cialist review and advice should be sought for patients with
prior HSV keratitis. Routine prophylaxis to suppress virus
replication should be considered for patients with recurrent
attacks and/or who are already taking intermittent suppres-
sive antiviral therapy. Aciclovir 400 mg twice daily,
valaciclovir 500 mg daily, or famciclovir 250 mg twice daily
are suitable as prophylaxis138
4.2.4. Diagnostic approach, screening and treatment of
the underlying infection
4.2.4.1. Diagnostic approach and screening. Detection of
HSV antibodies indicates prior exposure and ongoing latent
infection with HSV, but screening is not required. Serolog-
ical responses appear late and are unsuitable for diagnosis.
Patients with ophthalmic or genital symptoms should be
referred for specialist assessment. See VZV section for
laboratory diagnosis of HSV in skin lesions.
4.2.4.2. Treatment of the infection. Aciclovir or the oral
prodrugs valaciclovir or famciclovir in therapeutic doses
for HSV.
4.2.5. Infection occurring during immunomodulator therapy
HSV reactivation often runs a mild, self-limited course, not
requiring discontinuation of immunomodulators or systemic
antiviral therapy.139 Nevertheless, immunomodulators should
not be initiated during active HSV infection, since it may be
exacerbated or even disseminate during immunosuppressive
therapy.93 Caution for possible HSV dissemination is warranted
when considering azathioprine in a patient with active orofacial
or genital HSV. Although extremely rare, HSV may cause
hepatitis,132,133 encephalitis,121 colitis,125–128 or pneumonitis123
during immunosuppressive therapy for IBD. Antiviral therapy
with intravenous aciclovir or foscarnet and discontinuation of
immunosuppressants are appropriate.125,126,128 HSV encephali-
tis and other severe or life-threatening manifestations of HSV
warrant careful multidisciplinary management. Whether or
when anti-TNF treatment can be reinstituted and the need for
valaciclovir/aciclovir prophylaxis warrants careful consider-
ation on a case-by case basis.119 HSV colitis is very rare even in
patients with IBD, but it might cause or mimic an acute
relapse.125–128 The risk of colectomy is high.126
4.3. Varicella zoster virus (VZV)
ECCO Statement OI 4D
Immunomodulator therapy should not be commenced
during active infection with chickenpox or herpes
zoster [EL4]. In the event of VZV infection during
immunomodulator therapy, antiviral treatment should
be started promptly [EL1] and immunomodulator
therapy discontinued in severe cases if possible [EL5].
Immunomodulator therapy can be reintroduced after
all vesicles have crusted over and fever has resolved
[EL5]
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See supplementary material.
4.3.2. Impact of immunomodulator therapy on the natural
history of the disease
Chickenpox is more often severe or life threatening in
immunocompromised patients, causing pneumonia, hepati-
tis, encephalitis or haemorrhagic disorders (thrombocytope-
nia or disseminated intravascular coagulopathy).147,148 In a
review of VZV in IBD, five of 20 cases of varicella proved
fatal.149 IBD patients, especially those on immunomodula-
tors, had an increased risk of zoster: 1.21 for UC and 1.61 CD
in a case-controlled study.150 Shingles is also more severe
with an increased risk of post herpetic neuralgia.140,142
Among 32 reported IBD patients with shingles, 25 were
receiving thiopurines, 14 as monotherapy. Seven patients
had evidence of visceral dissemination, including five with
CNS disease.149
4.3.3. Preventive measures
In countries with a policy of routine childhood vaccination,
the live virus varicella vaccine is given at 12–18 months with
a booster at 4–6 years. Two doses of varicella vaccine
provide protection from severe chickenpox.140,148,151
At diagnosis of IBD, unvaccinated adults and children
should be screened by history of chicken pox (or shingles) for
susceptibility to primary infection.124 If the history is
uncertain or negative, or the patient grew up in a tropical
or subtropical climate, they should be tested for varicella
zoster virus IgG.124,149,152 It is important to avoid testing a
sample which may contain VZV IgG obtained passively for
example by blood transfusion.
Where possible, seronegative immunocompetent patients
with IBD should receive two doses of varicella vaccine, a
month or more apart, completing the course at least 3 weeks
before any immunomodulators are started.151,153,154 Subse-
quent immunisation should only be administered 3–6 months
following cessation of all immunosuppressive therapy, includ-
ing high dose steroid monotherapy.155,156 Adults receiving
40 mg of prednisolone (or equivalent) daily for a week or
more are deemed to be on high dose steroids, as are
children receiving prednisolone, orally or rectally, at
2 mg/kg/day for at least one week, or 1 mg/kg/day for
one month.156
4.3.3.1. Post-exposure prophylaxis. Varicella zoster immune
globulin (VZIG) should be administered within 10 days when anunimmunised, seronegative, high-risk patient with IBD (immu-
nosuppression, pregnancy) has had significant exposure to
chicken pox, disseminated zoster, or shingles on exposed
skin.151,153,157,158 After VZIG, patients should be observed for
28 days, and treated in the event of varicella.151,153
4.3.3.2. Zoster vaccine. 14 times more potent than the
matching live varicella vaccine, provides significant protection
from both zoster and post herpetic neuralgia.159 It is licensed
in many countries and a single dose is routinely recommended
for immunocompetent individuals of over 60 years.160
Immunisation of IBD patients receiving immunomodulators
would require significant immunomodulator-free periods
before and after administration as outlined for varicella
vaccination. According to US CDC Guidelines however, therapy
with low-doses of methotrexate (≤0.4 mg/kg/week) azathio-
prine (≤3.0 mg/kg/day) or 6-mercaptopurine (≤1.5 mg/kg/
day) are not considered sufficiently immunosuppressive
to create vaccine safety concerns and are not regarded
as contraindications for administration of zoster vaccine.160
Recent data from Zhang et al. indicates that zoster vaccinemay
be safe in patients treated with anti-TNF.161 Still, the efficacy
and safety of this vaccination strategy is not clear in IBD patients
treated with immunomodulators so physicians should remain
cautious and further data are needed.
4.3.4. Diagnostic approach, screening and treatment of
the underlying infection
4.3.4.1. Diagnostic approach and screening. Serology is not
useful for diagnosis of chickenpox or shingles. VZV can readily
be detected in blister material scraped or swabbed from a
disrupted skin lesion. The choice of test depends on the
available technology. Nucleic acid amplification technology
tests are specific and sensitive (both approaching 100%), and
can detect VZV DNA in crusted lesions, although deemed no
longer infectious.162 Older technologies, including rapid antigen
detection, Tzanck smear (for multinucleate giant cells), and
electron microscopy, are more reliant on the quality and timing
of the sample, and the skill of the microscopist. Positive
Tzanck or electron microscopy tests do not differenti-
ate between VZV and HSV.162 Commercial tests for VZV
IgG have suboptimal sensitivity but work is underway to
improve the reliability and to define antibody cut-off
levels for susceptibility.163 Available tests are not
optimised to detect antibody to the vaccine virus.163
4.3.4.2. Treatment of the infection. Suspected varicella
or zoster warrants prompt action in IBD, and therapy
should be initiated pending test results. VZV requires
higher treatment doses than HSV, and the newer agents
valaciclovir or famciclovir, with higher oral bioavailability,
are preferable to acyclovir when oral therapy is
appropriate.140,141
4.3.5. Infection occurring during immunomodulator
therapy
Immunomodulators should not be initiated during
chickenpox or shingles. Patients should be carefully
assessed, and treated promptly with specialist advice.141
It may be advisable to stop immunomodulator therapy
until clinical resolution.149,164–170
454 J.F. Rahier et al.4.4. Epstein–Barr virus (EBV)ECCO Statement OI 4E
Screening for EBV infection before initiation of immu-
nomodulator therapy should be considered [EL5]. In
severe primary clinical EBV infection during immuno-
modulator therapy, antiviral therapy may be consid-
ered and immunomodulator therapy discontinued
[EL5]. In the event of EBV-driven lymphoproliferative
disease during immunomodulator therapy, the patient
should be managed in conjunction with appropriate
specialists. Immunomodulators should be stopped.4.4.1. Background
See supplementary material.
4.4.2. Impact of immunomodulator therapy on the natural
history of the disease
In the normal host, EBV infected B-cells persist in the
circulation with minimal expression of latency genes,
thereby avoiding destruction by EBV-specific cytotoxic
T-lymphocytes.172 When T-cell immunosurveillance is
impaired, eg post-transplant, enhanced EBV latent gene
expression drives the proliferation of EBV-infected
B-cells, and the attendant risk of post-transplant lym-
phoproliferation/lymphoma (PTLD).172,173 Primary EBV
infection in the first post-transplant year is associated
with a much increased risk of PTLD.171,174,175EBV IgG
testing pre-transplant identifies susceptible patients and
coupled with post-transplant EBV DNA surveillance facil-
itates early recognition of primary infection and prompt
reduction of immunosuppression.174
In recent years accumulated data has shown an in-
creased, albeit small, risk of lymphoma among IBD patients,
especially those on thiopurines.176–179 In the Cesame cohort
of almost 20,000 patients, current thiopurine therapy had a
hazard ratio of 5.28 for development of lymphoproliferative
disorder.176 The overall risk remains small, estimated to
result in one additional lymphoma for every 300–1400 years
of thiopurine treatment, but EBV seems to be implicated,
with a propensity for intestinal presentation.176–180 In
Cesame cohort patients on thiopurines, 12 of the 15
lymphomas were PTLD-like (and usually EBV-associated),
versus 1 of 8 lymphomas in patients not on thiopurine
therapy. Primary EBV infection may pose a particular threat:
among 6 patients under 50 years in the thiopurine group,
two males had fatal infectious mononucleosis associated
lymphoproliferative disorders.176 Two additional cases of
fatal infectious mononucleosis have been reported in CD
patients on azathioprine.181,182
4.4.3. Preventive measures
No EBV vaccine is available. Prophylaxis with aciclovir or
ganciclovir after renal transplantation has been reported to
reduce the risk of lymphoma in renal transplant recipi-
ents,174 but the risk of lymphoma in IBD is too low to justify
this approach.EBV IgG screening should be considered before
initiation of immunomodulator therapy.176,183 Anti-TNF
monotherapy could then be used in preference to
thiopurines in EBV seronegative patients at the clinician's
discretion.4.4.4. Diagnostic approach, screening and treatment of
the underlying infection4.4.4.1. Diagnostic approach and screening. The Paul–
Bunnell and monospot tests are suboptimal for diagnosis.
Primary EBV infection is diagnosed by the detection IgM
and IgG directed against the EBV viral capsid antigen (VCA)
with negative EBNA1 IgG. EBNA1 IgG usually appears weeks
or months later.184 Post-transplant EBV viral load monitoring
has a high sensitivity for current or future EBV-associated PTLD
in high risk HSCT and seronegative solid organ transplant
recipients, but poor specificity.185,186 The limited IBD data
shows negligible or self-limited increases in sequential EBV
viral load measurements after introduction of immunomodula-
tors, without associated EBV-associated disease.110,187 Biopsy
diagnosis and classification by a specialist haematopathologist
is required to differentiate infectious mononucleosis from
lymphoproliferative disease, non-Hodgkin's lymphoma and
Hodgkin's disease. Analysis must include EBER in situ
hybridisation to detect the presence of EBV.188 Immuno-
histochemistry for EBV is not an adequate substitute as
viral proteins e.g. LMP-1 are often not expressed.188,1894.4.4.2. Treatment of the infection. Aciclovir therapy
does not ameliorate the course of infectious mononu-
cleosis in otherwise healthy individuals.190 Steroid
therapy may be indicated for airway obstruction.
Anti-viral agents have no proven role in the treatment
of established PTLD, reflecting the limited productive
viral infection.1754.4.5. Infection occurring during immunomodulator therapy
Possible primary EBV infection warrants careful clinical
assessment, with full blood count and blood film, liver
function tests and EBV serology. Immunomodulator therapy
should be reduced or discontinued if possible. In severe
primary EBV infection, antiviral therapy with ganciclovir or
foscarnet may be considered, despite the lack of
supporting evidence.175,190 These agents are more potent
than aciclovir for replicative EBV infection, but are more
toxic.
Specialist advice should be sought for investigation and
management of suspected lymphoproliferative disease/
lymphoma. Discontinuation of immunosuppressive therapy
may result in spontaneous regression of EBV-associated
lymphoproliferative disease.175,191,192 In the absence
of spontaneous regression, or progression after interrup-
tion of immunomodulators, rituximab is the next line
of therapy for CD20 positive B-cell EBV-associated
lymphoproliferative disease. Chemotherapy may also be
required.
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Regular gynaecologic screening for cervical cancer is
strongly recommended for women with IBD, especially
if treated with immunomodulators [EL2]. In patients
with extensive cutaneous warts and/or condylomata,
discontinuation of immunomodulator therapy should be
considered [EL5]. Routine prophylactic HPV vaccina-
tion is recommended for females and males according
to national guidelines [EL2]. Current or past infection
with HPV is not a contraindication for immunomodula-
tor therapy [EL2]4.5.1. Background
See supplementary material.4.5.2. Impact of immunomodulator therapy on natural
history on the disease
It is unclear how immunomodulators can modify the course of
the disease, but there are reports of viral reactivation in
immunocompromised patients198,199 Several studies in women
undergoing organ transplantation demonstrated an increased
risk of cervical dysplasia, HPV infection and persistence.200–203
Moreover, studies inwomen affected by IBD also observed that
HPV-associated Pap-smears abnormalities were more fre-
quent.204,205 Therefore, immunosuppressive agents including
TNF blockers could increase the risk of persistent HPV
infection and ultimately cervical cancer.4.5.3. Preventive measures
Since 2006 a prophylactic quadrivalent vaccine (Gardasil ®,
Silgard®) using L1 virus-like particles (VLP) of HPV-6, -11, -16
and -18 is available in Europe. In 2007, a bivalent vaccine
(Cervarix®) containing L1 VLPs of HPV-16 and -18 was
approved in Europe. Both vaccines are highly immunogenic,
safe and offer high protection (95–100%) against HPV infection
in immunocompetent patients.206,207Depending on local guide-
lines, routine HPV vaccination is recommended for females
aged 11–14 years before onset of sexual activity. In the event
of missed or delayed vaccination, local guidelines variably
recommend HPV vaccination to females younger than 26 years
old, in some cases depending on beginning of sexual
activity.208 The quadrivalent vaccine is now recommended
in USA for males too aged 11–12 years old, with catch-up
vaccination for those younger than 26 years old208 HPV
immunisation uses a non-live agent, so it can be administered
to immunocompromised IBD patients. American guidelines
propose to recommend it to immunocompromised persons
through age 26 years (males and females) who did not get any
or all doses when they were younger.208 A recent study
investigated 37 females with IBD, 51% being treated with
anti-TNF agents and 49% receiving immunosuppressants.209
Interestingly, in this small study 3 doses of the HPV vaccine
Gardasil® were highly immunogenic and without significant
vaccine-associated side effects.4.5.4. Diagnostic approach, screening and treatment of
the underlying infection
Measurement of serum antibodies (IgG and IgA) to
type-specific virus-like particles (VLPs) or capsids is a useful
marker of prevalent or persistent HPV exposure and reflects
infection whatever the anatomical site. Such antibodies are
inadequate for diagnosis of HPV infection, because not all
patients seroconvert after HPV exposure and HPV antibodies
can take a year or more to appear.210,211 Identification of
HPV DNA via PCR is specific for diagnosis of a HPV infection,
but since HPV infection is transient and usually clears within
2 years, it is limited to the detection of current infection.212
Cervical smear testing in immunocompromised women
is recommended as for the general population.213,214 A
practical point is to ask female patients on immunomodula-
tors whether they have had a cervical smear. HPV screening
is not recommended for men in the general population,
because there is currently no evidence that screening or
treatment reduces the risk of progression to (anal) cancer in
this group.1934.5.4.1. Treatment of the infection. No antiviral agents
for eradicating or treating of HPV infections are known.
Treatment options for HPV-associated carcinoma include
surgery, chemo- and radiotherapy.213,2154.5.5. Infection occurring during immunomodulator therapy
Few studies describe a higher prevalence of abnormal
cervical (‘Pap’) smears associated with HPV-16 and -18 in
women with IBD compared to the general population. The
risk of an abnormal smear associated with HPV-16 and -18
has also been reported to increase in patients on immuno-
modulator therapy.204,205,216 On the contrary, a large
retrospective case–control study in Scotland did not find
any difference in rates of abnormal smears between IBD
women and controls.217 In all studies, confounding factors
like smoking and sexual activity are rarely explored. Even if
data still remain conflicting, women with IBD and especially
those on immunomodulators are best advised to have
regularly screening as high risk patients according to local
or ACOG guidelines.218 The American Cancer Society recent-
ly recommended that women who are immunocompromised
should be tested twice during the first year of diagnosis and
annually thereafter.219 They may be considered candidates
for HPV vaccine regardless of their sexual history.204,205
Nevertheless, infection with HPV is no contraindication to
immunosuppression. Anal carcinoma and squamous cell
carcinoma (SCC) in particular are considered rare complica-
tions of IBD (perhaps more common in those with chronic
fistulizing Crohn's disease) and may be associated with
infection with carcinogenic types of HPV.215
There are reports of an increased frequency of anogenital
warts in immunocompromised patients.220 Discontinuation of
immunomodulators may be helpful in patients with extensive
anogenital warts. Infection with HPV while on immunomodu-
lators does not otherwise present a clinical problem, although
there are occasional cases of disseminated cutaneous warts in
patients who have been on azathioprine for years. Treatment
is best conducted with a dermatologist, but the risk of
exacerbating the underlying IBD by withdrawing azathioprine
has to be considered and discussed with the patient. Extensive
456 J.F. Rahier et al.genital warts in psoriasis patients undergoing anti-TNF therapy
have been reported in small case series.221,222
4.6. Influenza virusECCO Statement OI 4G
Patients on immunomodulator therapy are considered
to carry an enhanced risk for the development of
severe influenza infection [EL5]. Annual vaccination
with trivalent inactivated influenza vaccine is an
effective strategy to prevent influenza [EL1]. The live
attenuated vaccine is not recommended. Vaccination
does not appear to have an impact on the activity of
inflammatory bowel disease [EL3]. Routine influenza
vaccination of patients on immunomodulators is rec-
ommended in accordance with national guidelines
[EL5]. Seroconversion after influenza vaccine is re-
duced in patients receiving immunomodulator therapy,
particularly in those on combination therapy [EL3]ECCO Statement OI 4H
Immunosuppressed patients with a laboratory diagnosis
of influenza should receive prompt treatment early in
the course of illness, whether or not an influenza
epidemic has been declared. Empiric treatment should
be given on clinical grounds during an epidemic in
accordance with national guidelines [EL5]4.6.1. Background
See supplementary material.
4.6.2. Impact of immunomodulator therapy on natural
history on the disease
Limited data exist on the epidemiology of influenza
infection in patients with IBD. While the incidence of
influenza does not appear greater in IBD patients receiving
immunomodulators,225 immunosuppression is generally
considered to enhance the risk of severe/complicated
influenza infection.226
4.6.3. Preventive measures
4.6.3.1. Vaccination. Annual vaccination is the most
effective method for preventing influenza virus infection
and is therefore recommended for patients on immuno-
modulators in guidelines from the American Center for
Disease Control (CDC).223 Two types of vaccines are
available. Live attenuated influenza vaccine (LAIV) should
only be used for healthy persons age 5–49 years and is not
recommended for patients on immunomodulators. In con-
trast, the trivalent inactivated influenza vaccine (TIV) may
be used for any person older than 6 months, including those
on immunomodulators.223 IBD patients on immunomodula-
tors are considered to be at risk and annual TIV vaccination
has been recommended.227 However, compliance with theserecommendations remains poor228,229 and definitive proof of
benefit is circumstantial.230 There is emerging data to suggest
that influenza vaccination may be less effective in patients
with IBD receiving immunosuppressants, particularly those
receiving combination therapy.231–233 The use of anti-TNF
monotherapy may also reduce response to vaccina-
tion.234,235 However, the immune response remains suffi-
cient to warrant annual influenza vaccination. Influenza
vaccination appears safe in patients with IBD and is not
associated with a risk of flare of disease.236
4.6.3.2. Chemoprophylaxis. Both oseltamivir and zanamivir
can decrease the risk of symptomatic infection, when given in
the early phase after close contact with a patient with
laboratory confirmed influenza.237,238 Recommendations re-
lating to the use of post-exposure prophylaxis for household
contacts show significant country to country variation.239 CDC
guidelines suggest chemoprophylaxis be considered if an
individual at high risk or influenza complications, such as an
IBD patient who is immunosuppressed, has a household
member or close contact with a person with influenza.240
4.6.4. Diagnostic approach, screening and treatment of
the underlying infection
4.6.4.1. Diagnostic approach and screening. Influenza is
characterised by the sudden onset of constitutional and
respiratory symptoms (myalgia, headache, malaise, cough,
core throat and rhinitis), typically with fever. In most cases,
the diagnosis is based upon symptoms and knowledge of the
local active prevalence of influenza infection. Diagnostic
tests for influenza can aid clinical judgment and include viral
culture, serology, rapid antigen testing, reverse transcrip-
tase–polymerase chain reaction (RT-PCR), and immunofluo-
rescence assays. Influenza antiviral agents should only be
used for treatment of acute clinical symptoms compatible
with influenza at a time when public health agencies report
that influenza is prevalent in the community, or when
influenza is specifically diagnosed by rapid antigen tests.240
4.6.4.2. Treatment of influenza infection. Four antiviral
agents with activity against influenza virus are available:
amantadine, rimantadine, zanamivir, and oseltamivir. Re-
sistance of influenza virus to amantadine and rimantadine is
appreciable, so these drugs are not currently recommend-
ed.240 When zanamivir or oseltamivir are started within 48 h
of the onset of symptoms, a reduction in fever and cough
from 1.5 days to 3 days has been demonstrated. Significant
differences compared to placebo were found only in those
treated within 36 h of onset for oseltamivir and within 30 h
of onset for zanamivir.241,242 Country specific European
guidelines recommend antiviral therapy for patients at high
risk of complications, except Germany where there is a
strong recommendation to treat all patients.239 Zanamivir
solution for intravenous injection or nebulisation has been
proposed in cases of complicated influenza or oseltamivir
resistance.240
4.6.5. Infection occurring during immunomodulator
therapy
CDC guidelines recommend early use of antiviral therapy
in suspected or confirmed influenza infection in all
ECCO Statement OI 5C
457Second European consensus on prevention, diagnosis and management of infections in IBDimmunocompromised patients, in order to reduce risk of
influenza-related complications.240
5. Parasitic and fungal infectionECCO Statement OI 5A
The risk of fungal infection in inflammatory bowel
disease seems to be low. Systemic infections are
exceptional, but mortality is high [EL4]. No vaccines
exist for prevention of fungal infection. Primary
chemoprophylaxis is currently not indicated. Secondary
chemoprophylaxis should be discussed with an appro-
priate specialist [EL5]
Screening for parasitic or fungal infection prior to
immunomodulator therapy is generally considered unnec-
essary. Specialist advice should be sought for patients that
have lived or travelled in endemic areas [EL5]5.1. Background and impact of immunomodulator
therapy on natural history of the disease
See supplementary material.
5.2. Preventives measures and screening
5.2.1. Immunisation and chemoprophylaxis for P. jiroveciECCO Statement OI 5B
No vaccines are available for prevention of P. jiroveci
pneumonia. For patients on triple immunomodulators
with one of these being either a calcineurin inhibitor or
anti-TNF therapy, standard prophylaxis with co-
trimoxazole is recommended if tolerated [EL4]. For
those on double immunomodulators, prophylactic co-
trimoxazole should be considered especially if one of
these is a calcineurin inhibitor [EL 4]There is no consistency in the approach to prophylaxis
against P. jiroveci in patients with IBD treated with
immunomodulators, despite some suggested guide-
lines.249,250 A meta-analysis showed a 91% reduction of
occurrence of P. jiroveci when chemoprophylaxis with
cotrimoxazole was administered in patients with
haemotological cancers or transplants.251 Patients with
HIV disease and a CD4+ count below 200/mL were at lower
risk with infections with P. jiroveci when maintained on
cotrimoxazole.252 It is rare for patients to acquire P.
jiroveci infection when the CD4+ count is above 200/mL.
There are multiple regimen for primary chemoprophylaxis:
Trimethoprim–sulphamethoxazole (TMP-SMZ) is the pro-
phylactic agent of choice with one-strength tablet daily
(80–400 mg) or half-dose daily of a double strength tablet
(160–800 mg) or a double-strength tablet three times per
week.5.2.2. Immunisation and chemoprophylaxis for parasitic
and fungal infections except P. jiroveciIn contrast to transplant patients, there is no evidence to
support a general policy of screening for parasitic or fungal
infections prior to initiating immunomodulator or biological
therapy. Patients returning from endemic areas or a past
history of parasitic or fungal infections represent special
cases. In the case of S. stercoralis, in particular, screening of
patients with risk factors could be performed, although
no method is ideal. Positive serology in a patient with a
compatible clinical history preparing to undergo steroid
therapy may be considered sufficient grounds for therapy
(with ivermectin ideally or with albendazol). Therapy could
be also considered in these patients even without a serology.
Specialist advice should be sought.
Secondary prophylaxis guidelines for Candida and Aspergillus
are available for transplant, cancer and ICU patients with
neutropenia, however IBD patients under immunosuppression
are not considered.253,254 Nevertheless, secondary prophylaxis
may be necessary in case of ongoing immunosuppressive
therapy but this should be discussed with appropriate
specialists.254
Specialist advice is recommended on the approach and
interpretation of diagnostic tests. The succinct details
in Table 1 are intended as a general guide for non-specialists.
P. jiroveci is now classified as an atypical fungus. Diagnosis is
based on the identification of P. jiroveci in bronchopulmonary
secretions obtained as induced sputum or BAL fluid. Serum
1,3-β-D-glycan assay may be helpful as a marker for the
diagnosis of P, jiroveci pneumonia with a sensitivity of more
than 90%.255 P. jiroveci trophozoites and cysts can be identified
by light microscopy and molecular techniques (high sensitivity
and specificity). A positive PCR may be found in asymptomatic
patient and should therefore be interpreted with caution
whereas a negative PCR value virtually excludes the infection.5.3. Treatment of the infection
Pulmonary involvement is a feature with most systemic
infections and fungal or parasitic pneumonia are potentially
life threatening. Systemic cryptococcosis can cause pneumo-
nia, butmore commonly causesmeningitis, sometimeswithout
meningism. Strongyloides hyperinfection with alveolar haem-
orrhage and disseminated disease is more frequently reported
in patients receiving high doses of steroids or other immuno-
modulators. The diagnosis should be suspected in any patient
with pneumonia from an endemic area. Eosinophilia is present
in up to 70% of the patients, and should raise suspicion of
infection with S. stercoralis,256 however severe cases may not
have eosinophilia. Early implementation of therapy (such as
parenteral ivermectin for disseminated strongyloidiasis) can
be life-saving.
Table 1 Summary of diagnostic approaches to parasitic and fungal infections.
Pathogen Culture Serology Molecular Other
Pneumocystis jiroveci − − +/− Direct visualization/cytology
Strongyloides stercoralis − + − Direct visualization/cytology
Toxoplasma gondii − + (+/−) Clinical context—radiology
Candida spp. + (+/−) (+/−)
Aspergillus spp. + + − Clinical context—radiology
Histoplasma capsulatum + + (+/−) Radiology + direct visualization(histology)/antigen detection
Cryptococcus neoformans + − − Cytology/antigen detection
ECCO Statement OI 6C
When active TB is diagnosed, anti TB-therapy must be
started, and anti-TNF therapy must be stopped but can
be resumed after two months if needed [EL4]
458 J.F. Rahier et al.General guidance for treatment of parasitic and fungal
infection is shown in Table 2. In patients with parasitic
or fungal infection, other than oral or vaginal candidiasis,
immunomodulator therapy should be stopped if possible
and standard therapy for the infection implemented.
Common sense dictates that if an opportunistic infection
arises as a consequence or in association with immunosup-
pression it is unwise to reintroduce such therapy in that
patient unless all other options are considered. If a
decision is made to reintroduce immunomodulator once
the infection has responded to treatment, because there
are no other options for controlling the IBD, then
consideration should be given to secondary prophylaxis
and specialist advice taken.
6. Mycobacterium tuberculosis infectionECCO Statement OI 6A
Reactivation of latent TB in patients treated with anti-
TNFs is increased and is more severe than in the
background population [EL2]. Latent TB should be
diagnosed by a combination of patient history, chest
X-ray, tuberculin skin test and interferon-gamma
release assays (IGRA) according to local prevalence
and national recommendations. Screening should be
considered at diagnosis and always performed prior to
anti-TNF therapy [EL5]. IGRA are likely to complement
the tuberculin skin test and are preferred in BCG-
immunised individuals [EL1]ECCO Statement OI 6B
Patients diagnosed with latent TB prior to anti-TNF should
be treatedwith a complete therapeutic regimen for latent
TB [EL1]. In other situations, specialist advice should be
sought. Chemotherapy for latent TBmay vary according to
geographic area or the patient's epidemiological back-
ground [EL5].When there is latent TB and active IBD, anti-
TNF therapy should be delayed for at least 3 weeks after
starting chemotherapy, except in cases of greater clinical
urgency and with specialist advice [EL5]6.1. Background
See supplementary material.
6.2. Preventive measures
International guidelines recommend TB risk evaluation before
anti-TNF therapy, based on epidemiological risk factors,
physical examination, chest X-ray, and tuberculin skin test
(TST) for latent TB, but there are local variations. A diagnosis of
latent TB should be consideredwhen there is a history of recent
exposure to the disease and positive initial tuberculin skin test
(TST) or positive booster TST or IGRA test and no radiological
evidence of active TB. A positive Mantoux reaction for TST is
defined by an induration diameter ≥5 mm. An abnormal chest
radiograph suggestive of old TB (calcification N5 mm, pleural
thickening, or linear opacities) should also be considered
suggestive of latent TB even if other criteria are absent.267–270
It is important to acknowledge that skin testing is sensitive,
but its specificity for predicting reactivation tuberculosis is
poor; only about 5% of immunocompetent persons with a
positive test will have progression from latent infection to
disease in their lifetime.271 Diagnosis of latent TB by TST may
be in particular distorted by prior BCG (Bacillus Calmette–
Guerin) vaccination, because vaccinated individuals may
become positive reactors to purified protein derivate (PPD).
This distortion is almost insignificant in adults above 30 years
of age, irrespective of age at vaccination or re-vaccination.
TST may also be false negative in patients on corticosteroids
for N1 month, or thiopurines or methotrexate for N3 months.
TST cannot adequately be interpreted if corticosteroids are
not discontinued for N1 month and immunomodulators for
N3 months. Consequently, a booster TST may be appropriate
for patients on immunomodulators with a negative TST
1–2 weeks after the first test. A false negative TST may also
occur during active IBDwithout immunosuppression. In clinical
practice, booster TST diagnoses 8–14% additional cases of
latent TB among rheumatologic or IBD patients.272–276 Any TST
≥5 mm should be considered positive for latent TB. Two new
Table 2 General guidance for treating parasitic or fungal infections.
Preferred regimen Second-line Duration
Pneumocystis jiroveci Co-trimazole (trimethoprim +
sulphamethoxazole)
Pentamidine 14–21 days
Strongyloides stercoralis Ivermectin Albendazole 2–3 days





Invasive Candida albicans a Fluconazole Caspofungin At least 14 days
Invasive Candida
non-albicans b
Fluconazole Voriconazole 2 weeks
Aspergilus spp. Voriconazole Amphotericin B deoxycholate Until resolution of
symptoms
Histoplasma capsulatum Amphotericin B liposomal
then Itraconazole
Amphotericin B deoxycholate 2–3 months
Cryptococcus neoformans Amphotericin B
deoxycholate + 5 Flucytosine
Fluconazole 10 weeks of induction and
consolidation treatment
(2 weeks of Amphhotericin B




a Invasive Candida albicans with history of Fluconazole use, fluconazole should not be the preferred regimen.
b in C. glabrata and C. krusei Voriconale or Echinocandin.
459Second European consensus on prevention, diagnosis and management of infections in IBDdiagnostic tests for tuberculosis infection have come on the
market and they belong to interferon-gamma release assays
(IGRAs), namely QuantiFERON–TB Gold (QFT) and the T-SPOT.
The two commercially available IGRAs both use purified
antigens from M. tuberculosis to stimulate peripheral-blood
lymphocytes to produce interferon-γ. The QFT test measures
the amount of interferon-γ in the supernatant of a cell
suspension, whereas the T-SPOT determines the number of
cells producing interferon-γ with the use of an ELISpot assay.
IGRAs are more likely to be positive in persons who have
recently been infected with M. tuberculosis, a group
at particularly high risk for disease progression.277 Another
potential advantage of the IGRAs is that there is no
cross-reactivity with the tuberculosis vaccine. Therefore,
IGRAs may be particularly valuable in evaluating tuberculosis-
infection status in persons who have received BCG vaccination
as younger than 10 years old. Nine studies encompassing 1309
patients with IBD were investigated in a recent meta-analysis.
The pooled concordance between the TST and IGRAs (QTF and
QTF in-Tube) was 85% and the concordance of the TST and
TSPOT.TB was 72%. Positivity was significantly influenced by
immunosuppression.278 Therefore, screening prior to initiation
of IST should be considered, particularly in those on anti-TNF.6.3. Impact of preventive action and
chemoprophylaxis
In a post-marketing surveillance of Infliximab among 5000
Japanese patients with rheumatoid arthritis, Takeuchi and
co-workers confirmed that chemoprophylaxis decreased
the number of cases with overt TB.279,280 TB chemopro-
phylaxis regimens are based on isoniazid (INH) for 6–
9 months.267,272,280–282 Individuals on chronic steroid ther-
apy, defined as the equivalent of greater than or equal to15 mg/day prednisone for at least 1 month, should receive
isoniazid prophylaxis if they have a positive TST.283,284
Randomised trials have shown that treatment is highly
effective, with approximately 90% protection provided
by completion of a 9-month course of isoniazid and 60
to 80% protection provided by completion of a 6-month
course.257 Rifapentine and isoniazid administered once a week
for 3 months, had a low rate of serious hepatotoxicity285
open-label randomised non-inferiority trial comparing 3 months
of directly observed once-weekly therapy with rifapentine
(900 mg) plus isoniazid (900 mg) (combination-therapy group)
with 9 months of self-administered daily isoniazid (300 mg)
(isoniazid-only group) in subjects at high risk for tuberculosis
was as effective as 9 months of isoniazid alone in preventing
tuberculosis.286 Although this association was not yet tested on
immunosuppressed patients.
Isoniazid-related hepatotoxicity occurs in approximate-
ly 0.15% of patients. It may occasionally be severe and
life-threatening. The risk of liver damage with isoniazid is
unrelated to the dose or blood concentration. An increased
risk of isoniazid-related hepatotoxicity in patients with
rheumatologic disease on concomitant methotrexate or
sulphasalazine has been reported, but the association has
not been established in IBD. Some authors advise monitor-
ing liver function at intervals, with cessation or alteration
of therapy if the transaminases exceed 3-fold associated
with hepatitis symptoms or jaundice, or 5-fold in the
absence of symptoms.273,280,287–290
No prospective or controlled data are available on the ideal
timing of anti-TNF therapy once TB treatment has begun. It
has been proposed that a pneumologist or infectious disease
specialist should supervise TB therapy. It has also been
suggested that anti-TNF treatment is either best delayed
until completion of an antituberculosis treatment and should
be avoided until at least 2 months after TB treatment has
460 J.F. Rahier et al.begun.291,292 There are no data assessing the impact of
thiopurine therapy on the risk of TB in patients also receiving
anti-TNF therapy. This suggests that thiopurines may be
continued during treatment of TB, although studies are
warranted.
7. Bacterial infection
7.1. Streptococcus pneumonia infectionECCO Statement OI 7A
Patients with IBD on immunomodulators are considered
to be at risk for pneumococcal infections [EL4]
ECCO Statement OI 7B
Pneumococcal vaccination should be given shortly
before initiation of immunomodulators [EL5]. Immunity
to S. pneumoniae after polysaccharide vaccination is
altered by immunosuppression [EL2]
ECCO Statement OI 7C
Immunomodulator therapy should be temporarily with-
held until the resolution of active infection. Treatment
of pneumonia in patients on immunomodulators must
always cover S. pneumoniae [EL5]
ECCO Statement OI 7D
Patients with inflammatory bowel disease on immuno-
modulator therapy with pneumonia should be tested
for L. pneumophila [EL4]. Immunomodulator therapy
should temporarily be withheld until resolution of the
active infection [EL5]See supplementary material.
As pneumococcal capsular antigens induce serotype specific
antibodies, both available vaccines (polysaccharide and poly-
saccharide conjugated) are able to produce serological
response.296 A 23-valent polysaccharide vaccine (PPV23) has
been available for many years and a 7-valent conjugate vaccine
(PCV7) has been licensed since 2001 in Europe. The 13-valent
pneumococcal conjugate vaccine (PCV13) provides the same
seroprotection as PCV7 and contains the 10 serotypes in PCV10
plus three additional pneumococcal serotypes: 3, 6A, and
19A297 PCV10 was originally approved with a 3 + 1 dosing
schedule but was recently approved for a 2 + 1 dosing schedule
in Europe.298 The PPV23 covers 80–90% of the serotypes
responsible for invasive pneumococcal disease in Europe.299
PPV23 vaccine is recommended in all older adults and in young
children (more than 2 years of age) who have a high risk for
pneumococcal disease.297 Primary vaccination and revaccina-
tion every 5 years with PPV23 arewell tolerated, induce robust,
long-lasting immune responses and are cost effective. In
children less than 2 years of age, the PCV7 seems to be
effective in the prevention of invasive disease, severe pneumo-
nia and serotype-specific otitis media.300 PPV23 vaccine should
ideally be administered before the start of immunomodulator
therapy, since immunomodulators may reduce the antibody
response. This has been shown in patients with rheumaticdiseases301–306 and IBD.307,308 Therefore, the vaccine is best
administered two weeks before the start of immunomodula-
tors.301 Advisory Committee on Immunization Practices (ACIP)
recommends that adults aged ≥19 years with immuno-
compromising conditions and who have not previously received
PCV13 or PPSV23 should receive a dose of PCV13 first, followed
by a dose of PPSV23 at least 8 weeks later. A second PPSV23
dose is recommended five years later. For those with previous
vaccination with PPSV 23, a PCV 13 dose should be given
≥1 year after the last PPSV23309
The most frequent and severe manifestations of pneu-
mococcal infection are pneumococcal pneumonia and
pneumococcal meningitis (with or without pneumococcal
bacteriemia). Antibiotic treatment of pneumonia in pa-
tients with IBD should always cover S. pneumoniae.
Penicillin is the standard antibiotic for penicillin-susceptible
pneumococcal pneumonia and meningitis, but local advice on
resistance is appropriate,310 especially since their immuno-
suppression may be associated with an increased risk of
penicillin resistance. In most European countries, in particular
in patients with meningitis, 3rd generation IV cephalosprins
are recommended. In invasive pneumococcal infection, im-
munomodulator therapy is best temporarily withheld until
resolution of the infection.293,295,311
7.2. Legionella pneumophila infectionSee supplementary material.
No vaccine is available and effective chemoprophylaxis has
not been described. The key to diagnosis is appropriate
sputummicrobiological culture. Antigen detection in the urine
(detects only L. pneumophila, serogroup 1; this accounts for
70 to 80% of cases) is easy done; direct fluorescent stain on
respiratory specimens has sensibility ranged from 25 to 75%.
Real-time PCR in throat swab specimens, bronchoalveolar
lavage (BAL), urine, and serum has not shown to be more
sensitive than culture, and therefore CDC does not recom-
mend the routine use of genetic probes or PCR for the
detection of Legionella in clinical samples321 Serological
testing is also available—a fourfold rise≥128 in titer between
the acute and convalescent titer is required for a definitive
serologic diagnosis.322
Empirical treatment of severe community-acquired pneu-
monia should always cover L. pneumophila especially in
the immunocompromised.323,324 Macrolide or fluoroquinolones
are the treatment of choice for L. pneumophila.312,316
Immunomodulator therapy is best temporarily withheld
until resolution of the active infection, however recurrent
infection has been reported. Therefore, careful consider-
ation is necessary about the benefit of continuing
immunomodulators.316
461Second European consensus on prevention, diagnosis and management of infections in IBD7.3. Salmonella species infectionECCO Statement OI 7E
Patients receiving immunomodulators are at risk of more
severe infections with Salmonella enteritidis and S.
typhimurium [EL4]. Prevention of Salmonella sp. infections
consists of food hygiene and careful food choices (avoiding
raw eggs, unpasteurised milk and insufficiently cooked or
raw meat) [EL5]. Immunomodulators should be temporar-
ily withheld until resolution of the active infection [EL5]
ECCO Statement OI 7H
Inflammatory bowel disease is an independent risk
factor for infection with Clostridium difficile. Patients
with colitis are particularly susceptible [EL3]See supplementary material.
Salmonellosis is treated with antibiotics such as fluoro-
quinolones or third-generation cephalosporins, depending on
the local susceptibility pattern. In rare cases of S. typhimurium
osteomyelitis333 or septic arthritis334 combination of antibiotics
and surgical treatment may be required. Immunomodulators
should be temporarily withheld until resolution of the active
infection as immunomodulator therapy is considered a high-risk
predisposing condition for intestinal or systemic infections with
Salmonella spp.335
7.4. Listeria monocytogenesECCO Statement OI 7F
Patients receiving immunomodulators are at risk
of systemic and central neurological infections with
L. monocytogenes [EL4]. The incidence appears higher
in patients treated with anti-TNF therapy compared to
other immunomodulators [EL 4]. Prevention includes
avoidance of unpasteurised milk, cheese, uncooked
meat, raw vegetables and smoked seafood [EL5]. Anti-
TNF therapy should be discontinued during infection.
A decision on restarting anti-TNF therapy should be
taken in conjunction with an infection specialist and
should involve a careful risk benefit.
ECCO Statement OI 7I
Chemoprophylaxis for CDAD is not warranted. Hygiene
procedures are recommended in a nosocomial setting
[EL2]
ECCO Statement OI 7J
Screening for C. difficile is recommended at every flare in
patients with colonic disease [EL3]. Diagnostic workup is
recommended according to test availability and local
practice. Available tests include glutamate dehydroge-
nase antigen and toxins A/B enzyme immunoassays,
bacterial culture and cytotoxicity assay and nucleic acid
amplification technology (NAT) tests
ECCO Statement OI 7K
Metronidazole and oral vancomycin are equally effective
in treatingmild tomoderate CDAD [EL1]. It remains to be
established if this applies to patients with inflammatorySee supplementary material.
Curative treatment consists of ampicillin, amoxicillin, or
sulphamethoxazole/trimethoprim in case of allergy to
penicillin.310 No data are available on whether immunomod-
ulators should be temporarily or indefinitely withheld in the
event of active infection. Nevertheless, there are some
reports of reinstitution of immunosuppression after treat-
ment of active infection.337
7.5. Nocardia speciesECCO Statement OI 7G
Patients receiving anti-TNF therapy have been reported
to be at risk of systemic and cutaneous infections with
Nocardia spp., particularly when they are also treated
with corticosteroids [EL4]. The risk of Nocardia spp.
infections may be reduced by avoiding soil contact with
broken skin and inhalation of soil-contaminated dust
[EL5]. A decision on restarting anti-TNF therapy should
be taken in conjunction with an infection specialist and
bowel disease. Other antibiotics should be stopped if
possible. For severe CDAD, vancomycin has been shown
to be superior in patients without inflammatory bowel
disease [EL1] and is therefore preferable. In CDAD, use of
immunomodulators should be guided by careful risk
benefit evaluation and clinical judgement [EL4]should involve a careful risk benefit evaluation [EL5]See supplementary material.
The patients should be treated with sulphamethoxazole/
trimethoprim and/or ceftriaxone or carbapenems alone or in
association and a specialist advice should be taken. It is
advisable to prolong the antibiotics until the disappearance
of all lesions.344
All immunocompromised patients and patients with
neurological involvement are best treated for at least one
year and some suggest indefinitely, especially if patients
continue to be immunosuppressed as a result of their
disease or treatment.324 In order to obtain complete
resolution of the infection, it has been suggested to
indefinitely discontinue anti-TNFα treatment.347,350
7.6. Clostridium difficile infectionSee supplementary material.
Immunomodulators are a known risk factor for C. difficile
infection and development of CDAD. Experience from solid
organ transplantation shows an increase in incidence and
severity of CDAD after transplantation.371 Glucocorticoids
ECCO Statement OI 8A
Inflammatory bowel disease need not restrict patients
from foreign travel. Patients travelling to developing
regions should have a pre-travel consultation. Special
consideration should be given to patients on immunomod-
ulators [EL5]. There is probably no overall increased rate
of IBD flares after travel-related enteric infections [EL3]
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for mortality in patients with CDAD.372,373 In a large
population-based cohort of IBD patients, corticosteroids,
irrespective of dose and duration, were associated with a
threefold increase in the risk of CDAD compared with other
immunomodulator or biological agents.374 Maintenance of
immunomodulators, but not biologic therapy, was indepen-
dently associated with CDAD in IBD.365
Antimicrobial stewardship, glove use, hand hygiene
with soap and not alcoholic solution and disposable
thermometers should be routinely used for the prevention
of healthcare-associated C. difficile infection.375 Patients
diagnosed with, or strongly suspected with infection,
should be placed in isolation or cohorted together, when
the number of cases is more than one.
In routine clinical practice, several different laborato-
ry tests can be used to diagnose infection. Some of them
detect the presence of toxins in the stools, such as the
enzyme immunoassays (EIAs) and the cytotoxicity
neutralisation assay (CCNA). Other targets the organism
itself, such as the glutamate dehydrogenase (GDH)
antigen assay or culture. Finally, molecular methods,
such as nucleic acid amplification technology (NAT) tests,
detect the presence of the toxin genes.376 Some assays
have also been created to test for hypervirulent strain,
with reported high sensitivity and specificity.377,378 There
are numerous commercially available EIAs for both toxins
A and B with good specificity but with lack of adequate
sensitivity for sole use as a diagnostic modality.362,379
Moreover, EIAs designed to detect only toxin A are likely
to underreport the infection, since toxin A-negative C.
difficile strains account for up to 3% of CDAD. EIAs for C.
difficile GDH can be useful as initial screening in a
multistep diagnostic approach.362,376 NAT technology by
amplifying the C. difficile toxin B gene could be used with
high sensitivity and specificity.380,381 Given its high
sensitivity and the potential for false positive results,
NAT test has been suggested in algorithms together with
EIAs.376 CCNA for C. difficile toxin B still represents the
diagnostic gold standard despite its long turnaround time
(24–48 h).382 Endoscopy cannot be recommended as a
diagnostic tool for CDAD383because pseudomembranes are
only rarely found and their absence does not exclude
infection. Pseudomembranes were only reported in 13% of
hospitalised IBD patients with CDAD, a finding that was
independent of immunomodulator use.384
In IBD patients, antibiotics use does not seem to play
same role as in the general population and only a 43% rate
of toxin-positive samples in active IBD patients with
previous antibiotic has been reported.354 Metronidazole
is generally first line therapy for patients experiencing a
first, or even a second episode of CDAD.385 The usual oral
treatment regimen is 200–250 mg four times daily or
400–500 mg three times daily for 10 to 14 days. Vanco-
mycin (i.e., oral form) is highly effective for CDAD and
preferable for multiple recurrences of CDAD, or if there
is local resistance to metronidazole.386 A recent
meta-analysis showed no statistically significant differ-
ence in efficacy between vancomycin and metronidazole,
or other antibiotics, including fusidic acid, nitazoxanide
or rifaximin.387 Similar results have been reported in
another updated systematic review.388 For patients withsymptoms of severe CDAD, or if the patient's condition
fails to improve or deteriorates on metronidazole, early
use of vancomycin is recommended.389 The dose of
vancomycin for acute CDAD is 125 mg P.O. every 6 h,
which is of equivalent efficacy to 500 mg four times
daily.390 To reduce the recurrence rate of CDAD, a tapered
or pulsed (125–500 mg every three days for 2–3 weeks)
treatment regimen with vancomycin has been pro-
posed.386 Other antibiotics, such as nitazoxanide and
rifaximin, may be considered in case of recurrent
disease.353 Tigecycline, an intravenous antibiotic with
good faecal penetration, has shown efficacy in the
treatment of severe, complicated or refractory CDAD.391
Data from a phase III trial showed that oral fidaxomicin
(200 mg twice a day for 10 days) was not inferior to oral
vancomycin in the treatment of mild to moderate CDAD.
Moreover, significantly fewer patients in the fidaxomicin
group than in the vancomycin group had a recurrence.392
Fecal bacteriotherapy has been proposed in the treatment
of recurrent CDAD, and a recent meta-analysis, including
27 studies with 317 patients, reported that fecal
bacteriotherapy was generally effective.393 Recurrent CDAD
has been effectively treated by Saccharomyces boulardii, but
evidence is still not sufficient to recommend probiotics.394,395
Thiopurine therapy, but not anti-TNFα therapy, has been
significantly associated with C. difficile infection.365 In a
retrospective multicentre European cohort study 12% of
patients given antibiotics and immunomodulators for CDAD
associated IBD flare reached a composite endpoint of death
or colectomy or in hospital megacolon, bowel perforation,
haemodynamic shock or respiratory failure. None of the
patients treated with antibiotics alone reached the endpoint
(p b 0.06). The use of more than one immunomodulator
increased the risk.396 A recent survey among gastroenterol-
ogists, however, reported significant disagreement on
whether combination of antibiotics plus immunomodulators
or antibiotics alone should be given to IBD patients with
CDAD-associated flares.397 Clearly the risk and benefit of
immunomodulator therapy should be balance in such
patients, but it remains a matter of clinical judgment as to
whether immunomodulators should be withdrawn. Steroids
have been reported to be of therapeutic value in severe
CDAD in a single small case-series398 so there seems no
reason to avoid corticosteroids.8. Special situations
8.1. Patients travelling frequently or travelling to
developing countries
ECCO Statement OI 8B
Pre-travel immunisation of IBD patients who are not on
immunomodulators should follow standard guidelines for
healthy travelers, according to travel destination [EL4]
ECCO Statement OI 8C
All patients with IBD should have Hepatitis A vaccina-
tion according to guidelines for the general population
before travel to endemic areas. The normal two dose
schedule should be completed, preferably before
travel [EL5]. Response to Hepatitis A immunisation in
IBD patients on immunomodulators should be checked
by serological assay [EL5]
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developing countries
The traveler with IBD is exposed to two main risks during
travel:
(i) Relapse, exacerbation, or complications of the under-
lying IBD due to gastrointestinal infections acquired
during travel, change in dietary habits, decreased
compliance or unavailability of IBD medication.
(ii) Acquiring infectious diseases endemic to developing
countries which may be more severe in IBD patients
who are immunosuppressed.
These patients are therefore best advised to consult their
gastroenterologist as well as a professional travel advisory
clinic prior to travel.
8.1.2. Pre-travel consultation
Pre-travel interventions should be evaluated for both safety
and efficacy. Patients with IBD should be provided with
adequate medication, instructions for emergency
self-treatment in the event of a disease exacerbation if
medical assistance is not readily available and adequate
health insurance, which includes cover for evacuation by air.
Guidelines regarding vaccinations and preventive measures
when travelling to less economically developed countries are
frequently updated by the Infectious Diseases Society of
America and the web sites and publications of CDC, eCDC
and WHO.399 Vaccine preventable diseases include: hepatitis
A, hepatitis B, typhoid fever, yellow fever, Japanese B
encephalitis, meningococcal meningitis, tick born encepha-
litis, poliomyelitis, influenza, mumps, measles, diphtheria,
and tetanus. Malaria, traveler's diarrhoea, tuberculosis and
insect-borne diseases, Influenza and sexual transmitted
diseases (STD) are also considered.
This section addresses three principal questions:
1. Do these diseases behave differently when affecting IBD
patients?
2. Do these diseases behave differently in IBD patients
treated with IM/biologicals?3. What is the degree of immunosuppression and what is its
influence on the success of preventive measures and on
their safety.8.1.3. Do these diseases behave differently in IBD
patients?
In a prospective case–control study of 71 IBD patients and
their companions travelling to non-industrialised areas of
the world, there was no increased rate of gastrointestinal
infections among the IBD travelers, although mild increase in
dermatological symptoms was noted.400 Similarly, a retro-
spective case–control study of 222 IBD travelers and 224
healthy controls, found no difference between the IBD and
the healthy groups in the rate of illness episodes during
travel to the tropics or to developing countries.401
Although several epidemiological studies indicate that
enteropathogens can provoke the initial onset of IBD and are
associated with reactivation of quiescent disease,402–404 a
recent retrospective study did not show increased rate of
IBD flares after traveling among 277 IBD patients, although
only 43% of them were travelling to non-industrialised
countries.405
8.1.4. Do travel-associated diseases behave differently in
patients on immunomodulators?
In a recent prospective study of 75 travelers to developing
countries who were receiving immunomodulator medications
(21 on systemic steroids and 19 on anti TNFs) and additional 71
IBD patients of whom 69% were on immunomodulators, there
was no travel-related preventable disease in any of these
immuno-suppressed patients or in their healthy travel com-
panions.400 In another study, out of 277 Dutch IBD travelers of
whom 43% were immunosuppressed, only 1 patient was
admitted to the hospital with salmonella enteritidis gastroen-
teritis which responded to conservative therapy but no control
group was reported.405 In a retrospective case-control study,
immunosuppressed IBD patients had a similar rate of illness
during trips to the tropics as did healthy control group. A
non-significant trend for increased illness episodes among
immuno-modulator treated patients compared to controls
(22% vs. 20%, P = 0.06) was observed when travelling to all
developing countries were considered.401 Finally, out of 75
immuno-suppressed renal transplant patients visiting develop-
ing countries, there were 4 illnesses requiring hospitalisation,
of which 2 were definitely infectious (cellulitis in one,
salmonella gastroenteritis in one)and both responded to
standard therapy.406
In addition to these studies, there are only scant case
reports regarding the contraction of travel-associated or
vaccine-preventable infections by immunocompromised pa-
tients. These include a fatal poliomyelitis in one patient
following administration of live oral polio vaccination to his
daughter and 8 patients with malaria, of which one was
fatal.407 Anti-TNF drugs have been associated with reacti-
vation of HBV in some patients and malaria (in one patient).
Thus, overall, it seems there is currently no documenta-
tion of direct effect of immunomodulators on the onset and
severity of vaccine-preventable, travel-associated diseases
in patients with inflammatory bowel disease. However, a
detrimental effect of immunomodulation cannot be defi-
nitely excluded due to the rarity of these events.
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and efficacy of preventive measures
Immunisation of patients with IBD against travel-associated
vaccine-preventable diseases is highly desirable, because
their altered immune status may predispose them to a more
severe course of some vaccine-preventable infections. Two
main issues have to be addressed when considering vaccina-
tion of patients with IBD on immunomodulators:ECCO Statement OI 8D
Patients with IBD are probably not more susceptible to
traveller's diarrhea than healthy individuals [EL3]. They
should pay close attention to precautions regarding
food and water during travel. The immunocompro-
mised patient should have a low threshold for initiating
self-therapy for traveller's diarrhoea with quinolones or
azithromycin [EL5]1. The safety of the vaccine and possibility of exacerbating
IBD due to vaccination.
2. The efficacy of vaccination and modes of monitoring
acquisition of immunity.
8.1.5.1. Vaccination safety. There are no reports of an
increased rate of adverse outcomes following immunisation
in patients with IBD not being treated with IMs. Further-
more, no vaccine has been shown to be associated with
the initiation or exacerbation of IBD, despite speculation
regarding the measles vaccine.408 This is notable given the
potential fatal outcome of measles in unimmunised patients,
and in light of recent data from Germany showing that 45% of
patients with IBD have not been vaccinated against measles
(see below).409
Killed, inactivated or recombinant vaccines have been
administered to many IBD patients with variable degrees of
immunosuppression, as well as to other immunosuppressed
patients (post-transplantation, rheumatic disorders, and
chronic pulmonary disease). Adequate humoral responses
to vaccination in immune-mediated inflammatory diseases
has been demonstrated for hepatitis B, influenza and
pneumococcal vaccination410
There are no reports of infectious complications caused
by killed or inactivated vaccines and adverse events have
been found to be similar to healthy controls. Therefore,
clinical guidelines consistently advocate vaccination of
immunosuppressed patients with inactivated vaccine for
appropriate indications.411–414 As a rule live vaccines are
contraindicated in individuals until 3–6 after all immuno-
modulator therapy has been discontinued.
8.1.5.2. Efficacy of vaccination. Development of immunity
following immunisation has been discussed in prior sections.
However, it is of note that diminished cellular and humoral
responses to the oral administration of Salmonella enteric
serovar Typhi Ty21a vaccine was found among UC patients
after colectomy compared to healthy individuals, presum-
ably due to lack of colonic colonisation by the bacteria.415
On the other hand, immunisation with oral inactivated
B-subunit whole-cell cholera vaccine was similarly effective
among UC patients after colectomy, compared to con-
trols.416 Thus, immunisation with parenteral inactivated S.
typhi Vi polysaccharide is preferred in patients with
inflammatory bowel disease who have had a colectomy and
for those on immunomodulators.
Hepatitis A vaccine: In one study, eight liver transplant
recipients were compared to 16 patients with chronic liver
disease. None of the transplant patients responded to HAV
vaccine, compared to 7 of 14 with chronic liver disease
(p b 0.02).417 In another study, 37 liver transplant recipients
were compared both to healthy controls and patients withchronic liver disease. Maximal seroconversion of transplanted
patients, observed at 7 months post-vaccination, was only
26%. No correlation was found with azathioprine or blood
levels of calcineurin inhibitors.418 Another study has reported
seroconversion rates up to 41% in liver transplant patients and
24% in renal transplant patients after HAV immunisation.419
In contrast with the transplant population data, a recent
prospective controlled study in 66 pediatric IBD patients, of
whom 49 were taking azathioprine and/or corticosteroids, the
rate of seroconversion was similarly high after the second dose
(N97%) in the IBD and the control groups, although the rate of
seroconversion was lower in the IBD group when measured
after the first dose.420
Measles vaccine: Measles can be severe or fatal in immu-
nocompetent children and adults, especially pregnant women.
Individuals with compromised immunity are at added risk
of measles encephalitis and pneumonia, which can present
insidiously, without rash, months after exposure. Measles
remains endemic in many countries with regular outbreaks
still occurring in Europe (http://www.who.int/immunization_
monitoring/diseases/big_measlesreportedcases6months_PDF.
pdf). Recent data from Germany show that 45% of
patients with IBD have not adequate immunisation against
measles.409
Evidence of immunity is provided by one of the following:
(i) serological evidence of measles (measles IgG positive),
(ii) being born before 1960 (virtually everyone had natural
measles) or (iii) having documentary evidence of 2 doses of
measles vaccine. Susceptible individuals should ideally be
vaccinated prior to initiation of any immunomodulator
therapy, and especially so if the patient is resident in, or
anticipates travel to, a region where local outbreaks are
occurring. The two dose schedule of measles-containing live
virus vaccines, given 4 weeks apart, affords lifelong protec-
tion. Immunomodulator therapy can then be initiated 3 weeks
or more following the second dose. When vaccination is not
possible due to ongoing immunomodulator treatment, house-
hold contacts should be vaccinated so that the patient can be
indirectly protected. Measles vaccine can safely be given to
immunocompetent individuals without prior testing as addi-
tional doses do not pose a problem. It is important to establish
measles-status even if vaccination is not feasible prior to
immunomodulator therapy. This is to facilitate prompt
administration of measles post-exposure prophylaxis with
human immunoglobulin or intravenous immunoglobulin to
susceptible immunocompromised patients.
8.2. Travellers' diarrhoea
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See supplementary material.
8.2.2. Treatment and self-treatment
See supplementary material.
8.3. Screening for latent tuberculosisECCO Statement OI 8E
The risk of M. tuberculosis infection in long term travellers
to countries with high-endemicity is of similar magnitude
to the average risk of the local population [EL2]. Patients
with IBD traveling for more than a month to a moderately
or highly endemic area should be advised to be screened
for latent tuberculosis. If negative, screening should
be repeated approximately 8–10 weeks after returning
[EL5]
ECCO Statement OI 8F
Returning travellers with diarrhea should have a stool
examination for bacterial pathogens, ova and parasites
and a complete blood count to identify eosinophilia. For
long term travellers with IBD returning from countries
highly endemic for strongyloidiasis, serological blood
test for strongyloidiasis should be considered [EL5]International travellers are at increased risk for tubercu-
losis, which may become evident months or years after
travel. In a multicentre, prospective cohort study, the risk of
M. tuberculosis infection in long-term immunocompetent
travelers to high-endemicity countries, was substantial. It
was of similar magnitude to the risk for the local popula-
tion.424 The clinician caring for patients with IBD may have
to consider the following:
(i) Immunosuppression favors progression of asymptom-
atic latent tuberculosis to active disease.
(ii) IBD patients not treated with immunomodulators at
the time of travel but who acquired (asymptomatic)
TB infection during travel, may be considered for
immunomodulators at a later stage.
Attempts should therefore be made to identify latent
tuberculosis infection in these patients. Areas that are
considered to be moderately to highly endemic for tubercu-
losis include most of the countries in Africa, Central America,
South and Southeast Asia, theMiddle East, the former states of
the Soviet Union and parts of South America. Long-term (more
than a month) travelers with IBD who had no screening test for
latent tuberculosis or have a negative screening N1 year
before traveling to these countries, are best advised to obtain
a tuberculin skin test and/or interferon-gamma release
assay (QuantiFERON TB-Gold test, or ELISPOT) before depar-
ture.425,426 If the result is negative, the test should
be repeated approximately 8–10 weeks after return.427,428
A two-step tuberculin skin test (for patients on immuno-
modulators) is recommended initially, particularly if pre-
vious exposure is likely. A positive tuberculin skin test or
interferon-gamma release assay is an indication for chest
radiograph examination and treatment. These recommen-
dations apply for the following IBD patients:
(i) Travelers with IBD to areas where tuberculosis is
moderately to highly endemic and who are receiving
immunomodulator therapy, regardless of the duration
of travel(ii) Travelers with IBD but without immunomodulators,
who travel for at least one month to areas where
tuberculosis is moderately to highly endemic
(iii) Travelers who might have prolonged exposure to
patients with active tuberculosis (such as hospitalised
patients, prisoners, or homeless population).
Particular consideration should be given to otherwise fit
youngsters with IBD who travel abroad before or after
University because they frequently travel for extended
periods, stay in cheap accommodation or engage in welfare
projects that might put them at higher risk. Of note, none of
the current methods for pre- and post-travel TB screening
approaches 100% sensitivity for diagnosing active tuberculosis.
8.4. Malaria
See supplementary material.
8.5. Prevention of insect bites
See supplementary material.
8.6. Guidelines for evaluating the returning travelerIt is beyond the scope of these guidelines to review the
large number of diseases that may affect the returning
traveler. Consequently the focus of this section is on specific
issues related to patients with IBD who return from developing
countries (see Section 8.3 for screening for latent tuberculosis
in the returning traveler).
8.6.1. General investigations
The returning traveler from long-term travel in developing
countries who suffers from diarrhea should have a full blood
count to identify eosinophilia, stool culture for enteric
pathogens and microscopy for ova, cysts and parasites.
This is particularly relevant to patients with IBD who are
immunosuppressed.
The sensitivity of microscopic examination of a single stool
specimen for the detection of ova, cysts and parasites
generally exceed 80%.429,430 Additional stool samples, as well
as immunofluorescence or enzyme immunoassay for specific
parasites, (e.g. Giardia lamblia, C. parvum, or Entamoeba
histolytica) increase the sensitivity.430,431 Parasitic infections
are more likely to be diagnosed in patients with prolonged
diarrhoea.432 Common non-infectious causes of chronic diar-
rhoea in returning travellers include postinfectious disacchari-
dase deficiency, irritable bowel syndrome and undiagnosed
latent disease such as villous atrophy. In many cases of
ECCO Statement OI 10A
A standardised check list, screening for risk of
opportunistic infections and adapted to local condi-
tions, should be completed, preferably at the diagnosis
of IBD [EL5]
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but symptoms usually resolve within one year.430,433
8.6.2. Strongyloidiasis
Strongyloidiasis deserves special consideration. In addition to
non-inflammatory diarrhoea that is often associated with
eosinophilia, S. stercoralis can produce overwhelming infec-
tion in immunocompromised persons, as a result of its unique
ability to replicate and increase in numbers without leaving its
host (autoinfection).434 Strongyloidiasis can persist indefinite-
ly in the host and cause hyperinfection years after acquisition
when host immunity is impaired, especially by corticosteroid
therapy.435 IBD patients returning from endemic areas
are best evaluated for possible strongyloidiasis, even in the
absence of symptoms or eosinophilia. Strongyloidiasis in
Europe may be more difficult to diagnosis in travel related
infections than in immigrants.436 and more severe in HTLV1
concomitant infected patients.437 The sensitivity of a single
stool examination is low and repeated stool examinations are
often needed. The diagnosis is oftenmade by serologic tests256
(Table 1). Many experts recommend therapy for seropositive
patients, despite negative stool examinations.
9. PediatricsECCO Statement OI 9A
Children presenting with IBD under the age of five often
have underlying immune deficiencies [EL4]. The present
ECCO recommendations, that overall are applicable to
the pediatric age group, should be interpretedwithmore
caution in this group of patients [EL5]
ECCO Statement OI 9B
In infants whose mothers were treated with biologics
during pregnancy, live vaccines should be withheld
until at least the age of 6 months [EL4]
ECCO Statement OI 9C
In children with IBD, initial treatment at diagnosis with
exclusive enteral nutrition offers a window to update
the patients' vaccination status [EL5]
ECCO Statement OI 10B
Vaccination history should be documented at diagnosis
and immunisation status regularly updated [EL5].
Vaccination is best given before immunomodulator
therapy [EL3]The overall recommendations regarding vaccinations
should be applied to paediatric and adolescent patients,
because, similar to adult IBD, they are also at increased risk
of infections For the pediatric age group, some specific
considerations are in needed.29 Vaccination schedules are
well established and regularly updated438 but need to be
reconsidered in cases of immune suppression.
In early onset IBD,i.e. under 5 years of age, underlying
immune deficiencies should be highly suspected.439–442
Special consideration should be given to the immunisation of
healthy infants whose mother receives biological treatmentsduring pregnancy. A recent study reports that anti-TNFs
(infliximab & adalimumab, but not certolizumab) crosses the
placental barrier and that the drug can be found in cord blood
and in the infant's serum for up to 6 months post-delivery.443 A
case of fatal systemic BCGitis from BCG vaccine in an infant
born to a mother treated with anti-TNF has been reported.444
Pediatricians should therefore avoid the administration of live
vaccines to such infants during the first 6 months of life.445
In pediatrics exclusive enteral nutrition is considered a
valuable alternative for induction therapy and could there-
fore be used as a window allowing time to complete and
optimise immunisations prior to prescribing immunosuppres-
sive agents.446,447
10. Vaccination and safety screening before
starting an immunosuppressive treatment10.1. Background
A standardized check list, screening for risk of opportunistic
infections is implemented into the routine clinical care of
patients with IBD since the emergence of the first consensus
report on the prevention, diagnosis and management of
opportunistic infections in inflammatory bowel disease by
the European Crohn's and Colitis Organization. These tools
are adapted to the regional conditions and standards of
care. The reduction of cases with tuberculosis during TNF
inhibitor therapy after implementation of tuberculosis
screening suggests that more comprehensive standardised
screening programs might reduce the risk of other opportu-
nistic infections associated with immunosuppressive treat-
ment as well.
A standardised check list can be download from ECCO




Ideally the medical history should cover:
– History of bacterial infections (especially urinary tract
infection)
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– Risk of latent or active tuberculosis: date of the last BCG
vaccination; potential contact with patients having
tuberculosis; country of origin, or prolonged stay in an
area endemic for tuberculosis; history of treatment for
latent or active tuberculosis
– History of varicella-zoster virus infection (chickenpox/
shingles)
– History of herpes simplex virus infection
– Immunisation status for hepatitis B
– History of travel and/or living in tropical area or countries
with endemic infections
– Future plans to travel abroad to endemic areas.
– Measles vaccination history
10.3. Physical examination
General physical examination best includes a search for
features that often pass without comment, because they
are of minor significance in people who are generally
healthy, but which may have substantial implications when
immunosuppressed:
– Systemic or local signs of active infection (including
gingivitis, oral or vaginal candidiasis, or intertrigo as
features of fungal infection)
– Cervical smear.
10.4. Laboratory tests
Some opportunistic infections are preventable and the
potential for severe infection during immunosuppression
can be ameliorated if thought is given to identifying risks
before starting immunomodulator therapy. Baseline tests
performed at diagnosis should include:
– Neutrophil and lymphocyte cell count; C reactive protein
– Urine analysis in patients with prior history of urinary
tract infection or urinary symptoms
– Varicella zoster virus (VZV) serology in patients without a
reliable history of varicella immunisation
– Hepatitis B and hepatitis C virus serologies
– Epstein–Barr virus serology
– Human immunodeficiency virus (HIV) serology after
appropriate counselling
– Eosinophil cell count, stool examination and strongyloi-
diasis serology (for returning travellers)
– Hepatitis A virus and measles serologies (physician
discretion).
10.5. Screening for tuberculosis
Screening for tuberculosis should be considered at diagnosis
of IBD before using high dose corticosteroids or immuno-
modulators other than anti-TNF therapy, although it is
considered mandatory for the latter group.
– Clinical context of risk (gathered from a detailed history,
above)
– Chest radiograph– Tuberculin skin test and/or interferon gamma release
assay (according to country-specific guidelines).
10.6. Vaccination
Vaccines are best given before introduction of immunomod-
ulator therapy. Consideration could reasonably be given to a
vaccination programme at diagnosis of inflammatory bowel
disease, since around 80% of patients will be treated with
corticosteroids, 40% with thiopurines and 20% with anti-TNF
therapy. As in the general population, the immunisation
status of patients with inflammatory bowel disease should
be checked and vaccination considered for routinely
administered vaccines: tetanus, diphtheria, poliomyelitis.
In addition, every patient with inflammatory bowel disease
should be considered for the five following vaccines. Please
refer to appropriate sections for dose and timing.
– VZV varicella vaccine (if there is no medical history of
chickenpox, shingles, or VZV vaccination and VZV serol-
ogy is negative
– Human papilloma virus
– Influenza (trivalent inactivated vaccine) once a year
– Pneumococcal vaccines (PCV 13 and PPSV 23)
– Hepatitis B vaccine.
Vaccines for patients on immunomodulators traveling in
developing countries or frequently traveling around the
world should be discussed with an appropriate specialist.
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.crohns.2013.12.013.
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